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GLOSSARY 
Cumulative risk The absolute risk, or probability of an event occurring over a specified time period. 
Family History A family history of disease in an individual is the occurrence of the disease in a blood relative of that individual. 
Gene A gene is a molecular unit of heredity of a living organism. 
Genetic Counselling A service delivered by a qualified health professional that provides a comprehensive evaluation of familial risk for 
inherited disorders using kindred analysis and other methods, patient education, discussion of the benefits and harms 
of genetic testing, interpretation of results after testing (consequences and nature of the disorder, probability of 
developing or transmitting it), and discussion of management options. 
Genetic Counsellor A healthcare professional providing individuals and families with information on the nature, inheritance, and implications 
of genetic disorders to help them make informed medical and personal decisions. If it is appropriate, they will discuss 
genetic testing, coordinate any testing, interpret test results, and review all additional testing, surveillance, surgical, or 
research options that are available to members of the family. 
Genetic testing Genetic testing is a type of medical test that identifies changes in chromosomes, genes, or proteins. The results of a 
genetic test can confirm or rule out a suspected genetic condition or help determine a person’s chance of developing or 
passing on a genetic disorder. 
Germline  The cells from which eggs or sperm (i.e., gametes) are derived. 
Lifetime risk The risk of developing a disease during one's lifetime or dying of the disease. 
Penetrance A characteristic of a genotype; it refers to the likelihood that a clinical condition will occur when a particular genotype is 
present. 
Proband The individual through whom a family with a genetic disorder is ascertained.  
Relatives – First-degree relatives These are the closest blood relatives (relatives by marriage do not count). These include father, mother, son, daughter, 
brother, sister. 
Relatives – Second-degree 
relatives 
These are blood related grandparents, grandchildren, uncle, aunt, nephews and nieces, half-brothers and half-sisters. 
They are on both the mother and father’s side of the family. 
Relatives – Third-degree relatives These are blood related great grandparents, great grandchildren, great uncle, great aunt, first cousin, grand nephew and 
grand niece. They are on both the mother and father’s side of the family. 

 
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■ SCIENTIFIC REPORT 1 INTRODUCTION 
This clinical practice guideline is based on the collaborative efforts of the 
Belgian Health Care Knowledge Centre (KCE), the College of Human 
Genetics and the College of Oncology. This guideline complements the 
practice guideline for breast cancer screening and is the second report in a 
short series of oncogenetic testing guidelines. 
1.1 Background 
Oncogenetic tests are tests that assist in the diagnosis of specific cancers 
that have an important hereditary component. Such tests may also assist to 
identify which family members are at risk of developing specific forms of 
cancer when one member is diagnosed with a breast/ovarian cancer.  
Criteria are needed for the identification and referral of individuals and 
patients to genetic centres for counselling, possibly followed by germline 
mutation analysis.  
About 5% of all breast cancers are largely attributable to inherited mutations 
in specific genes including BRCA1, BRCA2 and TP53 although there is 
considerable uncertainty around this figure, that may differ between 
countries. Patients may benefit from an early identification as preventive 
measures can be implemented, including enhanced surveillance, risk 
reducing surgery and chemoprophylaxis. 
According to NICE (2013),1 two key parameters are related to each other 
but should be clearly distinguished:  
 Breast cancer risk: the risk that the individual will develop breast (or 
ovarian) cancer in the future. Breast cancer risk is frequently expressed 
as either the lifetime risk of developing the disease or as risk in the next 
10 years. 
 Carrier probability: the probability that the individual carries a 
deleterious mutation in one of the known breast (or ovarian) cancer 
susceptibility genes.  
In the NICE guideline,1 the genes associated with inherited breast cancer 
risk are listed. ‘At least five genes (BRCA1, BRCA2, TP53, E-Cadherin, 
STK11) are known to be associated with a high breast cancer risk (greater 
than 30% lifetime risk), but it is important to emphasise that these genes are 
not the only cause for familial breast cancer. It has been estimated that these 
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genes explain about 25% of the excess familial risk of breast cancer. Most 
of the remainder is likely to be due to low to moderate penetrance alleles. 
Of the known high risk genes, deleterious alleles of BRCA1 and BRCA2 are 
most common. Carriers of mutations in these genes have a high lifetime risk 
of breast cancer (variously estimated, depending on the context, as 65-85% 
for BRCA1 and 40-85% for BRCA2). Both genes also confer a high risk of 
ovarian cancer (around 40-50% for BRCA1, 10-25% for BRCA2) as well as 
more moderately increased risks of other cancers. BRCA1 and BRCA2 
mutations explain a considerable proportion of very high risk families (that 
is, families with four or more close relatives with breast cancer), particularly 
if there is also a family history of ovarian cancer or of male breast cancer. 
Mutations in these genes are however rare in the general population, and 
probably only account for about 2% of breast cancer cases overall. 
Mutations in the TP53 gene predispose to a very high risk of breast cancer, 
such that the majority of women are affected before the age of 50. Mutations 
in this gene also predispose to a range of other cancers including childhood 
sarcomas and brain tumours, and mutations are therefore usually identified 
when these cancers occur together in families, a syndrome known as Li-
Fraumeni syndrome. Mutations in TP53 are significantly rarer than BRCA1 
or BRCA2 mutations. When considering genetic testing, as well as testing 
for the well known BRCA1, BRCA2 and TP53 genes, it may be important to 
consider other genes associated with a potentially high risk of breast cancer 
such as PTEN, Peutz-Jegher’s syndrome and E-cadherin, where clinically 
appropriate. Mutations in the PTEN gene are responsible for Cowden’s 
syndrome, a very rare inherited disorder associated with an increased risk 
of breast cancer. Mutations in two other genes, ATM and CHEK2, are 
associated with moderate risks of breast cancer; clinical genetic testing for 
these genes has not been implemented.’1 
1.2 The need for a guideline 
Criteria are needed for the identification and referral of patients with breast 
and/or ovarian cancer and their family members to genetic centres for 
counselling, possibly followed by germline mutation analysis. It is important 
to provide such guidance to all clinicians active in the field. In addition, the 
                                                     
a  Moreover, a reimbursement is foreseen for tests performed abroad (if no 
Belgian specialised laboratory is able to perform the test) for diagnostic 
topic is timely. Firstly because the new nomenclature, introduced on 
1/1/2013, for genetic tests (article 33) and the agreement on genetic testing 
consultation led to distribute the NIHDI budget between genetic counselling 
(€4,288 millions) and laboratory procedures (€37,795 millions)a. This new 
convention implies the development of genetic counselling activities by 
genetic centres. Secondly, because beyond Apart from a number of high 
penetrance genes, BRCA 1 and BRCA 2, TP53 for Li-Fraumeni syndrome 
and PTEN for Cowden syndrome, involved in familial risk for breast cancer 
and ovarian cancer, an increasing number of moderate- and low-penetrance 
genes are being identified. There is a need to standardise the use of 
oncogenetic tests based on the available evidence. Early identification of 
women at risk makes the initiation of life saving strategies possible, including 
enhanced surveillance, risk reducing surgery and chemoprophylaxis. 
1.3 Scope 
This guideline will cover following populations: 
 Adult women (18 years and older) without breast cancer who may be at 
increased risk of developing breast cancer because of a family history 
of breast, ovarian or a related cancer;  
 Adult women (18 years and older) with a recent diagnosis of breast 
cancer and a family history of breast, ovarian or a related cancer.  
 Men affected with male breast cancer. 
Children are not covered by this guideline. 
The guideline will cover following issues: 
 Who qualifies for a genetic test or criteria for genetic testing; 
 Tests for which genes have clinical utility; 
 What follow-up is recommended depending on test results and family 
history. 
analysis of DNA samples from patients (and their relatives) suffering from rare 
cancers or rare diseases. 
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In two separate chapters we focused on the same issues for two more 
specific syndromes that are associated with an increased risk for breast 
cancer: 
 Cowden syndrome 
 Li-Fraumeni syndrome 
However, we did not cover three syndromes that are also associated with 
an increased risk for breast cancer, i.e. Peutz-Jeghers (associated with 
STK11),  Ataxia Telangiectasia (associated with ATM) and Hereditary 
Diffuse Gastric Cancer (associated with CDH1), neurofibromatosis type 1 
(associated with NF1 mutations) or multiple endocrine neoplasia type 1 
(caused by germline mutations in the MEN1 tumor-suppressor gene).2 
Moreover, it does not cover subsequent prophylactic treatment such as 
chemoprevention (e.g. Tamoxifen) or risk-reducing surgery.  
1.4 Remit of the guideline 
1.4.1 Overall objectives 
This guideline provides recommendations based on current scientific 
evidence for the diagnosis and follow-up of persons at increased familial risk 
for breast and/or ovarian cancer. Clinicians are encouraged to interpret 
these recommendations in the context of the individual person situation, 
values and preferences.  
The guidelines are based on clinical evidence and may not always be in line 
with the current criteria for NIHDI (RIZIV/INAMI) reimbursement of 
diagnostic and therapeutic interventions. The NIHDI may consider 
adaptation of reimbursement/funding criteria based on these guidelines. 
1.4.2 Target users of the guideline 
This guideline is intended to be used by care providers involved in genetic 
counseling, testing and follow-up of patients with hereditary breast cancer, 
Li-Fraumeni syndrome and Cowden syndrome, in particular. It also contains 
recommendations for persons that must decide when to refer for genetic 
counselling and testing such as general practitioners, gynaecologists, 
oncologists, surgeons, radiologists and pathologists. It can also be of 
interest for patients and their families, hospital managers and policy makers. 
1.5 Statement of intent 
Clinical Guidelines are designed to improve the quality of health care and 
decrease the use of unnecessary or harmful interventions. This guideline 
has been developed by geneticists, oncologists, gynaecologists and 
researchers for use within the Belgian healthcare context. It provides advice 
regarding the care and management of patients with hereditary breast 
cancer, Li-Fraumeni syndrome and Cowden syndrome to care providers 
involved in genetic counseling, testing and follow-up of these patients. 
The recommendations are not intended to indicate an exclusive course of 
action or to serve as a standard of care. Standards of care are determined 
on the basis of all the available clinical data for an individual case and are 
subject to change as scientific knowledge and technology advance and 
patterns of care evolve. Variations, which take into account individual 
circumstances, clinical judgement and patient choice, may also be 
appropriate. The information in this guideline is not a substitute for proper 
diagnosis, treatment or the provision of advice by an appropriate health 
professional. It is advised, however, that significant deviations from the 
national guideline are fully documented in the patient’s file at the time the 
relevant decision is taken. 
1.6 Funding and declaration of interest 
KCE is a federal institution funded for the largest part by INAMI/RIZIV, but 
also by the Federal Public Service of Health, Food chain Safety and 
Environment, and the Federal Public Service of Social Security. The 
development of clinical practice guidelines is part of the legal mission of the 
KCE. Although the development of guidelines is paid by KCE’s budget, the 
sole mission of the KCE is providing scientifically valid information. KCE has 
no interest in companies (commercial or non-commercial i.e. hospitals and 
universities), associations (e.g. professional associations, unions), 
individuals or organisations (e.g. lobby groups) that could be positively or 
negatively affected (financially or in any other way) by the implementation of 
these guidelines. All clinicians involved in the Guideline Development Group 
(GDG) or the peer-review process completed a declaration of interest form. 
Information on potential conflicts of interest is published in the colophon of 
this report. All members of the KCE Expert Team make yearly declarations 
of interest and further details of these are available upon request. 
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2 METHODOLOGY 
2.1 Introduction 
The KCE guideline is produced according to highly codified principles, based 
on scientific information regularly updated from the international literature. 
This guideline was developed using a standard methodology based on a 
systematic review of the evidence. Further details about KCE and the 
guideline development methodology are available at 
https://kce.fgov.be/content/kce-processes. 
Several steps were followed to elaborate this guideline. Firstly, clinical 
questions were developed and the inclusion and exclusion criteria were 
defined in collaboration with members of the Guideline Development Group 
(see Appendix 1). Secondly, a literature review was conducted (including a 
search for recent, high quality guidelines). Thirdly, on the basis of the results 
of the literature review, recommendations were formulated. As the GRADE 
approach currently only applies for treatment interventions and not yet for 
diagnostic interventions, no grading of the recommendations was performed 
for this guideline. 
2.2 The Guideline Development Group 
This guideline was developed as a result of a collaboration between 
multidisciplinary groups of practising clinicians, geneticists and KCE 
experts. The composition of the GDG is documented in Appendix 1. The 
GDG consists of all authors listed in the colophon. 
Guideline development and literature review expertise, support, and 
facilitation were provided by the KCE Expert Team.  
The roles assigned to the GDG were:  
 To provide feedback on the selection of studies and identify further 
relevant manuscripts which may have been missed; 
 To provide feedback on the content of the guideline; 
 To provide judgement about indirectness of evidence; 
 To provide feedback on the draft recommendations; 
 To address additional concerns to be reported under a section on ‘other 
considerations’. 
2.3 Clinical research questions 
The CPG addressed the following clinical questions: 
 Hereditary breast cancer 
o How to select the women who may have a hereditary risk of breast 
cancer based on family history? 
 What are the existing assessment tools? 
 What are their validity and their applicability in the Belgian 
context? 
o How to select the women where a possible hereditary raised risk of 
breast cancer was identified who are eligible for a genetic test? 
 What are the existing assessment tools? 
 What are their validity and their applicability in Belgian context? 
o Tests for which genes have clinical utility? 
 Li-Fraumeni syndrome 
o What are the testing criteria? 
o What are the existing assessment tools? 
o What are their validity and their applicability in the Belgian context? 
 Cowden syndrome 
o What are the testing criteria? 
o What are the existing assessment tools? 
o What are their validity and their applicability in the Belgian context? 
2.4 General approach 
To verify if high-quality, recent guidelines are available that address the 
clinical research questions, a GCP project always starts with a search for 
published guidelines. If such guidelines are available, the ADAPTE 
methodology is followed (www.adapte.org). However, we assessed and 
summarized the underlying evidence where the recommendations of the 
guideline were based on. We only took over the recommendation if the GDG 
agreed with the interpretation and considered the guideline applicable to the 
Belgian context. 
If no high-quality, recent guidelines are available, the general approach 
begins with the search for systematic reviews. 
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For each research question, a search for systematic reviews was conducted 
in MEDLINE, Embase and The Cochrane Library (Cochrane Database of 
Systematic Reviews, DARE and HTA database). If a recent high-quality 
systematic review was available, a search for primary studies published after 
the search date of the review was performed in MEDLINE and Embase. If 
no systematic review was available, a search for primary studies was 
performed in the same databases, without time restriction. Members of the 
guideline development group (GDG) were also consulted to identify 
additional relevant evidence that may have been missed by the search. The 
website 'Gene reviews' was consulted ad hoc for clarification as, while 
providing interesting background information, it is mainly based on expert 
opinion. 
2.5 Literature search and study selection 
2.5.1 Study design 
 Inclusion criteria for the study design: 
o Diagnostic studies: systematic reviews, guidelines, meta-analyses, 
RCTs, prospective studies;  
 Articles in Dutch, English, French and German were included. 
 Exclusion criteria for study design 
o Narrative review 
o Cadaver/animal studies  
o Case reports 
o Studies presented as conference abstract only. If no full-text was 
available, the study was not taken into account for the final 
recommendations. 
 An iterative approach was followed: 
o First, the search focused on clinical guidelines of high quality; 
o Second, a search for recently published systematic reviews and 
meta-analyses (SR/MA) published after the search date of the 
selected clinical guidelines was performed; 
o Third, the selected evidence synthesis was updated by a search 
for all relevant primary studies (RCTs and prospective studies) 
published after the search date of the selected SR/MA. 
To be included, a systematic review had to: 
 address at least one of the research questions; 
 search MEDLINE and at least one other electronic database; 
If more than one systematic review was identified for a particular research 
question, the focus was on the most complete systematic review. 
To be included, a primary study had to:  
 be an RCT, an observational study or a diagnostic accuracy study; 
 address at least one of the research questions. 
2.5.2 Databases and date limits 
The following databases were included in the literature search:   
 The Cochrane Database of systematic reviews 
(http://www.cochrane.org) 
 Medline (http://www.ncbi.nlm.nih.gov/pubmed)  
 Embase (http://www.embase.com/) 
For the guidelines the search engines were:  
 G.I.N. guideline resource (http://www.g-i-n.net) 
 National Comprehensive Cancer Network (NCCN) http://www.nccn.org/  
 National Guideline Clearinghouse http://www.guideline.gov/  
 NICE guidelines (http://www.nice.org.uk) 
Members of the GDG were also consulted to identify relevant evidence that 
might have been missed during the search process. 
2.5.3 Search strategy 
A combination of appropriate MeSH terms and free text words was used. 
The search strategy, PICO’s used to build the search strategy and number 
of articles per database are detailed in Appendix 2. 
Studies were screened on title and abstract by one researcher (Jo Robays) 
with the PICO in- and exclusion criteria. In case of doubt, the content experts 
were consulted. First, the titles and abstracts of the identified studies were 
checked and irrelevant studies were eliminated. In a second step, the 
remaining papers were screened by reading their full-text. If no full-text was 
available, the study was excluded for the final recommendations. Reference 
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lists of the selected studies were hand-searched for additional relevant 
manuscripts. Due to limited resources, only articles available through the 
Vesalius Documentation and Information centre or Interlibrary Loan were 
retained. 
The screening of the guidelines was performed on title and abstract by one 
researcher (Jo Robays) based on the PICO in- and exclusion criteria. 
2.6 Quality appraisal 
2.6.1 Clinical practice guidelines 
The elements evaluating the rigour of development from the AGREE II 
instrument was used to evaluate the methodological quality of the identified 
international guidelines (www.agreetrust.org). We also took editorial 
independence into account. Based on an overall assessment, 2 high-quality 
guidelines were identified (i.e. AHRQ and NICE). The document issued by 
AHRQ did not contain clinical recommendations; however, we can use the 
systematic review done in preparation of those recommendations (to be 
issued by the U.S. Preventive Services Task Force Recommendation). 
Moreover, 1 additional guideline (NCCN) did not have a reported search 
strategy but was used for reference tracking and for comparison with the 2 
other guidelines.  
2.6.2 Systematic reviews  
Selected (systematic) reviews were critically appraised by a single KCE 
expert (Jo Robays) using the AMSTAR checklist 
(http://amstar.ca/Amstar_Checklist.php).3 In case of doubt, a second KCE 
expert was consulted. As AMSTAR cannot readily be used for systematic 
reviews of genetic association studies we complemented this with guidance 
from the Human Genome Epidemiology Network.4 
Critical appraisal of each study was performed by a single KCE expert (Jo 
Robays). In case of doubt, a second KCE expert was consulted.  
2.7 Data extraction  
For each included CPG the relevant recommendations were extracted. 
For each systematic review, the search date, publication year, included 
studies and main results were extracted. For RCTs and longitudinal studies, 
the following data were extracted: publication year, study population, study 
intervention and outcomes.  
Data extraction was performed by one researcher (Jo Robays) and entered 
in evidence tables using standard KCE templates. Any disagreements were 
resolved by discussion or, if required, by a third party. All evidence tables 
are reported in Appendix 3. 
2.8 Grading evidence 
Due to current methodological limitations of the GRADE system for 
diagnostic tests, GRADE was not applied to the recommendations on 
diagnosis.  
2.9 Formulation of recommendations 
Based on the retrieved evidence, the first draft of recommendations was 
prepared by a small working group (KCE experts and GDG members). This 
first draft was, together with the evidence tables, circulated to the guideline 
development group 2 weeks prior to the face-to-face meetings (30th April 
2014). Recommendations were changed if important new evidence 
supported this change. Based on the discussion meetings a second draft of 
recommendations was prepared and once more circulated to the guideline 
development group for final approval (betwen 15th May 2014 and 2nd June 
2014).  
2.10 External review 
2.10.1 Healthcare professionals 
The recommendations prepared by the guideline development group were 
circulated to Professional Associations of physicians targeted by this 
guideline (Table 1). Each association was asked to assign one or two key 
representatives to act as external reviewers of the draft guideline. All 
representatives and their association are listed in the colophon under the 
section stakeholders as are their declarations of interest. 
Globally, 11 external experts were involved in the evaluation of the clinical 
recommendations. All invited panellists received the scientific report for all 
research questions and were asked to indicate their level of agreement with 
the recommendation, with a score of ‘1’ indicating ‘completely disagree’, ‘2’ 
‘somewhat disagree’, and ‘3’ ‘completely agree’ (the panellists were also 
able to answer ‘not applicable’ if they were not familiar with the underlying 
evidence). If panellists disagreed with the recommendation, they were asked 
to provide an explanation supported by appropriate evidence and to suggest 
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a more appropriate formulation. Scientific arguments reported by these 
experts were used to adapt the formulation of the clinical recommendations.  
Table 1 – List of Professional Associations invited 
 Belgian Section of Breast Surgery (BSBS) 
 Belgian Society for Human Genetics (BeSHG) 
 Belgian Society for Surgical Oncology (BSSO) 
 Belgian Society of Medical Oncology (BSMO) 
 Belgian Society of Pathology - Belgische Vereniging 
Anatomopathologie - Société Belge d'Anatomopathologie: no 
representative appointed 
 Belgische Genootschap voor Nucleaire Geneeskunde - Société 
Belge de Médecine Nucléaire: no representative appointed 
 Belgische Vereniging voor Radiotherapie-Oncologie - Association 
Belge de Radiothérapie-Oncologie (BVRO - ABRO): no 
representative appointed 
 College of Human Genetics 
 Domus Medica 
 Groupement des Gynécologues Obstétriciens de Langue Française 
de Belgique (GGOLFB) 
 Royal Belgian Radiological Society - Koninklijke Belgische Vereniging 
voor Radiologie - Société Royale Belge de Radiologie (RBRS): no 
representative appointed 
 Royal Belgian Society for Surgery (RBSS) 
 Société Belge de Sénologie (SBS) – Belgische Vereniging voor 
Senologie (BVS) 
 Société Scientifique de Médecine Générale (SSMG) : no 
representative appointed 
 Vlaamse Vereniging voor Obstetrie en Gynaecologie (VVOG) 
 
2.10.2 Patient representatives 
Associations of patient representatives (Vlaamse Liga tegen Kanker, 
Fondation contre le Cancer, Europa Donna, BRCA.be) were contacted to 
invite patient representatives to take part in the stakeholder meeting (16th 
October 2014). A key role for patient representatives is to ensure that patient 
views and experiences inform the group’s work. The patient representatives 
were asked to review the recommendations and add comments from a 
patients’ perspective where needed. 
For each recommendation where the patient representatives had a 
comment or suggestion, this was reported under ‘other considerations’. 
2.11 Final validation 
As part of the standard KCE procedures, an external scientific evaluation of 
the report was conducted prior to its publication. The current guideline was 
reviewed by 4 independent assessors (cf. names in the colophon). Their 
comments and questions were forwarded to the GDG in order to finalize the 
scientific report (November 2014).  
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3 CLINICAL RECOMMENDATIONS 
3.1 Hereditary breast cancer 
3.1.1 Criteria for referral to a centre of human genetics specialized 
in cancer genetics and follow-up of women at-risk of 
hereditary breast cancer 
In the KCE report 172  ‘Identifying women at risk for breast cancer/technical 
methods for breast cancer screening’5 the following criteria were listed for 
referral of women to a centre of human genetics specialized in cancer 
genetics (these criteria were developed for a screening; women affected 
with breast cancer were out of scope): 
Patients considered at high risk (that is, a 10-year risk at age 40–49 
years of greater than 8% or a lifetime risk of 30% or greater): 
 two first-degree or second-degree relatives diagnosed with breast 
cancer at younger than an average age of 50 years (at least one must 
be a first-degree relative), or 
 three first-degree or second-degree relatives diagnosed with breast 
cancer at younger than an average age of 60 years (at least one must 
be a first-degree relative), or 
 four relatives diagnosed with breast cancer at any age (at least one must 
be a first-degree relative). 
OR one of the following is present in the family history 
 Jewish ancestry 
 bilateral breast cancer 
 male breast cancer 
 ovarian cancer 
 sarcoma in a relative younger than 45 years of age 
 glioma or childhood adrenal cortical carcinomas 
 complicated patterns of multiple cancers at a young age 
These recommendations were based on the NICE guideline (2005) and 
systematic reviews. The recommendations were made in the context of 
breast cancer screening.  
The updated NICE guideline (2013)1 gave similar recommendations. In 
addition, it reported recommendations on when to refer for counseling and 
testing persons affected with triple negative breast cancer under the age of 
40 years. 
The NICE guideline (2013)1 also recommended the referral of patients with 
known cancer predisposing gene change in the family, e.g. BRCA1, BRCA2, 
TP53. AHRQ guideline6 reported and endorsed the NCCN guideline, that 
formulated similar recommendations to those put forward in the NICE 
guideline. 
There is no direct evidence for these criteria, all guidelines based their 
recommendations on observational evidence. They based their risk 
classification in average, moderate and high risk on data from both Claus 
and co-workers (1994)7 and the Collaborative Group on Hormonal Factors 
in Breast Cancer study, where a meta-analysis was performed using the 
primary data of 52 epidemiological studies (2001).8 
Belgian consensus based criteria were recently developed by the College 
for Medical Geneticists and reported in 'Guidelines for hereditary breast 
and/or ovarian cancer syndrome diagnostic testing criteria' (available at 
http://www.beshg.be). 
3.1.2 Models that assess the risk of carrying a germline mutation, 
such as BRCA1, BRCA2 and TP53 mutations 
There are two classes of models commonly used in clinical practice. 
A first class of models estimates the risk of developing breast cancer, either 
expressed as a 5 years, 10 years or lifetime risk, i.e. risk prediction models. 
A second branch of models assesses the risk of carrying a germline 
mutation such as BRCA1, BRCA2 and TP53 mutations, i.e. ‘carrier 
prediction models’ and not the risk of developing breast cancer. They are 
nearly all evaluated in specialized genetic clinics and aim at reducing the 
need for expensive genetic testing. Some of those models have extensions 
that enable them to assess or estimate the breast cancer risk. These models 
are not tested on cohorts but in transversal studies, where the model serves 
as ‘test’ and where the results of genetic testing are applied as ‘gold 
standard’. In the KCE report 172  ‘Identifying women at risk for breast 
cancer/technical methods for breast cancer screening’5 we reviewed the 
evidence concerning both types of models focusing on both discriminative 
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power and calibration. Discriminative power is the ability of a model to 
predict which women carry a mutation. 
We found moderate discriminative power with areas under the curve ranging 
from 0.71 to 0.85. Calibration, that is the ability of the model to give a correct 
prediction of the proportion of germline mutation positive patients in the 
tested populations, was mostly assessed in either US or British test 
populations and it is unclear to what degree this can be extrapolated to the 
Belgian context. 
NICE reviewed 26 studies of carrier probability models (BOADICEA, 
BRCAPRO, IBIS, MYRIAD, MANCHESTER, PENN, PENN II and FHAT) but 
also the performance of risk counselors. They found moderate quality but 
consistent evidence that carrier prediction models performed significantly 
better than chance with typical area under the receiver operator 
characteristics (AUROC) curve values between 0.7 and 0.8. They did not 
provide proof that one model performs better than the other nor that they 
perform better than risk counselors. The estimated AUROC for risk 
counselors ranged from 0.69 to 0.70. They found that the BOADICEA model 
was well calibrated to the British data, but it is unclear if this also applies to 
the Belgian context.9   
In UK, NICE proposed a formal cut-off point for mutation prediction models 
of 10%, allegedly based on a formal cost-effectiveness analysis of their own 
making. However, this analysis shows that a 5% cut-off point is also cost-
effective and that the difference in ICER is marginal. Reason to adopt this 
higher threshold is the potential risk to overload the existing service by 
increasing the number of patients eligible for genetic testing if the threshold 
would be lowered to 5%.  
AHRQ6 reached similar conclusions. Both NICE and AHRQ considered 
FHAT and MANCHESTER suitable for use in first line or second line, but 
stated that other models are more difficult to use and be better suited for 
specialized centers. However, uncertainty on key parameters was high and 
it is unclear to what degree the results are applicable to the Belgian context. 
3.1.3 Genes with low- and moderate-penetrance 
Cancer predisposing genes can be categorized according to their relative 
risk of a particular type of cancer. High-penetrant genes are associated with 
a cancer relative risk higher than 5. Low-penetrant genes are presented with 
relative risk around 1.5, whereas moderate-penetrant genes confer relative 
cancer risks from 1.5 to 5.10 Rare moderate-penetrant genes are CHEK2, 
ATM, BRIP1, and PALB2. Recent data suggest that the penetrance of 
PALB2 may be higher than reported before and that BRIP may be 
associated with increased risk of ovarian cancer only.11 
Zang et al.12 conducted a systematic literature search for candidate-gene 
association studies of breast-cancer risk. Meta-analyses were done for 279 
genetic variants in 128 candidate genes or chromosomal loci. They applied 
the Venice criteria to all significant associations identified by meta-analysis 
to evaluate the epidemiological credibility of each. Credibility was defined as 
strong, moderate, or weak, based on grades of A, B, or C in three categories: 
amount of evidence, replication of the association, and protection from bias. 
Globally, 51 variants in 40 genes showed significant associations with breast 
cancer risk. Cumulative epidemiological evidence of an association was 
graded as strong for ten variants in six genes (ATM, CASP8, CHEK2, 
CTLA4, NBN and TP53), moderate for four variants in four genes (ATM, 
CYP19A1, TERT and XRCC3), and weak for 37 variants. Additionally, in 
meta-analyses that included a minimum of 10 000 cases and 10 000 
controls, convincing evidence of no association with breast cancer risk was 
identified for 45 variants in 37 genes.  Details are given in the evidence 
tables (Appendix 3.2). 
Clinical implications of those genes remain unclear. Hostelle et al. (2010)13 
attribute this to the fact that moderate risk breast cancer susceptibility genes 
typically are encountered in a polygenic setting, meaning that several 
common low-risk breast cancer susceptibility alleles together confer 
increased breast cancer risks. When they do operate in a monogenic setting, 
their functional or clinical impact could be low. 
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After the search date of Zang et al. (2011),12 we identified 59 meta-analyses 
showing either inconclusive or no evidence for an association, or evidence 
of no or protective effect and 55 meta-analyses showing a weak effect. 
Because of the unclear clinical meaning of these findings, we did not perform 
an appraisal of these meta-analyses nor a data-extraction but listed them in 
Appendix 4.1. 
Attempts have been made to incorporate some of those genes in risk 
prediction models, but results were not convincing. Several authors 
attempted to improve models with genetic data. Wacholder (2010)14 
compared the Gail model with the modified Gail model using 10 common 
genetic variants associated with breast cancer and found that accuracy was 
only modestly improved, from an AUC of 0.580 to an AUC of 0.618. Mealiffe 
(2010)15 found a similar modest improvement for a model adding single-
nucleotide polymorphisms (SNP) with AUC of 0.594 compared with AUC of 
0.557 for Gail risk alone (p<0.001).  
Standard testing CHEK2 c.1100delC mutation: no consensus reached 
in the GDG  
The question on what to recommend concerning moderate penetrance 
genes in general  and CHEK2 in particular was extensively debated within 
the GDG and with some external validators. Different points of view 
remained. Here we try to summarize the different positions.  
In 2008, a meta-analysis of 26 000 patient cases and 27 000 controls 
concluded that the presence of this mutation results in a three- to five-fold 
increased risk of breast cancer.16 The authors of this meta-analysis argue 
that this increase in breast cancer risk implies that patients with a family 
history of breast cancer should be tested for the CHEK2 c.1100delC 
mutation together with BRCA1 and BRCA2 mutation screening. Others17 
immediately reacted saying that there is no compelling evidence to justify 
routine clinical testing for CHEK2*1100C to guide the management of 
families affected with breast cancer. 
In the populations where it is most prevalent (Northern and Eastern Europe), 
CHEK2*1100delC is seen in 1 of 100 to 1 of 200 individuals. Thus, testing 
for CHEK2*1100C will have the highest yield in such regions as the 
Netherlands, Finland, and Denmark, where the allele is the most frequent.17 
Until recently, this mutation was not routinely analyzed in the Netherlands. 
Since September 2014, all genetic centers in the Netherlands collectively 
decided to systematically test for the CHEK2 c.1100delC mutation when a 
BRCA1 and BRCA2 mutation analysis is being performed (see 
http://www.vkgn.org/nieuws/279-uitbreiding-van-dna-diagnostiek-naar-
erfelijke-borstkanker; accessed on November 24th 2014). The reason for the 
change in the attitude in the Netherlands (switching from not testing to 
testing) is a recent large study from Kriege et al. (2014) in which one Dutch 
hereditary non-BRCA1/2 breast cancer patient cohort (n=1 220) and two 
Dutch cohorts unselected for family history (n=1 014 and n=2 488, 
respectively) were genotyped for CHEK2 1100delC.18 In total, 193 (4.1%) of 
the 4 722 included female breast cancer patients were tested positive for the 
CHEK2 1100delC mutation. The CHEK2 1100delC-associated breast 
cancer was associated with a higher contralateral breast cancer rate 
(multivariate hazard ratio 3.97, 95% CI 2.59–6.07) as well as worse breast 
cancer-specific survival beyond 6 years after diagnosis (multivariate hazard 
ratio 2.05 (95% CI 1.41–2.99). The incidence of contralateral breast cancer 
in CHEK2 1100delC mutation carriers found in this study was high (10-year 
risk 24.1%). Follow-up strategies in clinical practice are impacted, since 
more intensive follow-up scheme for contralateral breast cancer detection 
already offered for affected BRCA1/2 mutation carriers (MRI or risk-reducing 
contralateral mastectomy) are suggested to also be an option for CHEK2 
1100delC mutation carriers after breast cancer diagnosis. 
The majority of the genetic centers in Belgium, but not all of them, are 
currently routinely analyzing the CHEK2 c.1100delC mutation in each 
patient who is tested for BRCA1 and BRCA2 and are communicating the 
result to the patient. 
3.1.4 Screening and follow-up of patients identified to be at risk 
In the KCE report 172  ‘Identifying women at risk for breast cancer/technical 
methods for breast cancer screening’5 we formulated the following 
recommendations: "For women at proven high-risk for breast cancer, yearly 
MRI and mammography is recommended from the age of 30 years onwards 
or starting five years before the age of the youngest diagnosed family 
member with breast cancer. This recommendation was based on the fact 
that available evidence showed a significantly increased sensitivity 
compared to mammography or mammography and ultrasound combined 
and that reported sensitivity for MRI varied between 68% and 100% in a 
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high-risk population. The use of ultrasound can be considered to shorten the 
interval or as adjunct to a positive mammography or MRI". 
The NICE guideline1 recommended to offer annual MRI surveillance to all 
women aged 30–49 years with a personal history of breast cancer who 
remain at high risk of breast cancer, including those who have a BRCA1 or 
BRCA2 mutation but not to offer MRI surveillance to any woman aged 50 
years and over without a TP53 mutation unless mammography has shown 
a dense breast pattern. This recommendation is however based on a cost-
effectiveness study that used an ICER threshold of 20 000 pounds per QALY 
with annual mammography as comparator for this group. It is unclear to what 
degree this cost-effectiveness analysis is applicable to the Belgian context. 
NICE found moderate quality evidence that surveillance using MRI has 
better sensitivity for breast cancer than mammography, clinical breast 
examination or ultrasound. Surveillance with both MRI and mammography 
has better sensitivity than either test alone, based on two systematic 
reviews. The Warner et al. (2008)19 systematic review estimated breast 
cancer prevalence amongst high risk women undergoing surveillance as 
approximately 2%. Using their pooled sensitivities and specificities, the 
results from 1 000 combined MRI and mammography surveillance tests 
would include 17 true positives, 49 false positives, 931 true negatives and 3 
false negatives. Rijnsburger et al. (2010)20 analysed the relative sensitivity 
of mammography and MRI surveillance in three age groups: less than 40 
years, 40 to 49 years and 50 or older. MRI had better sensitivity than 
mammography in all three groups: 61% versus 33%, 83% versus 39% and 
67% versus 56% respectively. They found only very low level evidence of 
an effect on survival or quality of life for any form of intensified screening. 
The review of AHRQ6 did not identify studies that directly addressed the 
effectiveness of risk assessment, genetic counselling, and genetic testing in 
reducing cancer incidence and mortality. 
The NCCN guidelines21 recommended the combination of MRI and 
mammography from the age of 25 year on for high risk patients, without 
presenting evidence on the combination MRI and mammography compared 
to MRI alone that supports this combination. 
Because the two guidelines, NICE and AHRQ, were very recent and dealing 
with this issue, we did not conduct a primary update of the evidence for this 
topic.  
 
Conclusions 
 There is no direct evidence from RCTs demonstrating the impact of 
genetic testing and counselling on mortality and morbidity. There is 
observational evidence however and for ethical reasons it is unlikely that 
such an RCT will ever be conducted. 
 Family history remains the main tool for identification of persons that 
would benefit from genetic testing and counselling. 
 Risk assessment models show moderate discriminative power, 
calibration was good in UK and US but may differ in the Belgian context. 
There is no proof that they perform better than clinical judgment of 
genetic counsellors however. 
 Cumulative epidemiological evidence for low- and moderate-penetrance 
genes is variable and their clinical implications remain unclear. 
 There is observational evidence for surveillance with MRI and 
mammography in high risk patients but no RCT assessed its 
effectiveness. 
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Other considerations  
Factor Comment 
Balance between 
clinical benefits 
and harms 
The GDG insisted on the fact that testing should be done in preference in an affected individual. 
The GDG insisted on the fact that selection criteria are not sufficiently validated and precise and that there needs to be room for 
clinical judgement when assessing the risk and deciding on the referral to a center for cancer genetic testing and the decision to 
perform a test or not for hereditary breast cancer.  
The GDG considered that danger from radiation coming from mammography among women younger than 30 years old is too high and 
that a lot of prudence is necessary for the age group between 30 and 40 years. Therefore a recommendation on the use of 
mammography was added. 
The GDG considered that the recommendation put forward by NICE to take into account the youngest age at which a breast cancer is 
found is confusing, outdated and difficult to implement and therefore the recommendation was simplified to age 25. 
The GDG proposed to use a higher cut off point for triple negative breast cancer, with genetic screening in this population up to 60 
years (used by NCCN) instead of 40 years of age, as proposed by NICE, based on clinical experience and considering that these cut 
off points are not based on hard evidence. 
The GDG considered that for women who are BRCA positive, MRI and mammography should not be done concomitantly but be 
alternated so that one examination is done every 6 months. 
Quality of 
evidence   
Although there is no evidence from RCT on the impact of genetic testing the GDG considered that such RCTs are impossible and 
unethical to conduct. 
The GDG considered that, although no formal proof of its effectiveness exists, the guideline should leave the door open for detection 
of interval cancers with ultrasound in high risk patients. 
There is no proof that one mutation prediction model is better than the other. However, some are perceived as difficult to use by the 
GDG. Although tested mainly in UK and USA, the GDG considers that models are sufficiently applicable in our setting as there is no 
reason to assume that BRCA prevalences are very different in our context. A decision can be guided or assisted by the consensus 
document 'Guidelines for hereditary breast and/or ovarian cancer syndrome diagnostic testing criteria' published by the College for 
Medical Geneticists (available at http://www.beshg.be, Guidelines, Guidelines for gene analysis for HBOC) (see Appendix 5). 
Costs (resource 
allocation) 
Within the recent laws for breast clinics (AR/KB 26.04.2007), all coordinator breast clinics should have a formal link with a genetic 
centre in order to make agreements on genetic consultations. 
NICE proposes a formal cut-off point for mutation prediction models of 10%, allegedly based on a formal cost-effectiveness analysis of 
their own making. However, this analysis shows that a 5% cut-off point is also cost-effective and that the difference in ICER  is marginal.  
Moreover, it is unclear to what degree the used models, calibrated for the UK, are sufficiently comparable to the Belgian situation.  
In Belgium, both the GDG and the panel of stakeholders agree to use a pre-test probability of “5 to 10%” as a guidance. They argue 
that the cut-off point is dropping over time due to the rapid evolution in sequencing technologies (much more becomes possible at a 
decreasing cost), from 10% some years ago towards 5% in coming years.   
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Factor Comment 
Low- and moderate-penetrance genes could also be incorporated in gene panels and this would make them more affordable. However, 
gene panels pose particular interpretation problems. Although it is expected that there will be a push towards the use of these panels 
in the near future there are too many unresolved issues to make a recommendation on them.    
Patients values 
and preferences 
Patients’ representatives ask that a correct and understandable information be provided to individuals at increased genetic risk. A 
dedicated support in decision-making is important for the different phases of the process (referral, testing, steps after a positive or a 
negative test). It is important to clearly explain figures about the increased risk of (breast/ovarian) cancer. 
Balanced and understandable information about the pros and cons of the various decisions has to be provided (e.g. about surveillance 
by mammography).  
There's a need for good psychosocial support (by professionals and by fellow patients) when making choices, when informing children 
and family members about the genetic predisposition or with respect to fertility planning. 
A uniform policy followed by all Genetic Centres in Belgium is essential. 
It is important that general practitioners / oncologists / gynaecologists / psychologists are well informed (or trained) about genetic 
mutations. Currently, a lot of people are not referred or do not receive the correct information about various mutations due to a lack of 
knowledge of these professionals. 
 
Recommendations 
 GENERAL APPROACH 
For women with a family history suggesting a hereditary risk of breast cancer, referral to a centre of human genetics specialized in cancer genetics for 
counselling and testing should be considered, whether the woman is affected by breast cancer or not. If not affected, it is advisable that the referring physician 
asks the unaffected patient to refer an affected family member if possible. 
If possible, the genetic testing of a family should usually start with the testing of an affected individual (mutation searching/screening) to try to identify a mutation 
in the appropriate gene (such as BRCA1, BRCA2 or TP53). For affected women, the timing of counselling and testing should be compatible with the treatment 
that has to be installed. 
If a mutation is identified, further testing of family members should follow a stepwise approach, based on the degree of relationship. Exceptions to the stepwise 
approach for testing of family members can be made if the relatives died or cannot be reached for various reasons, taking into account elements of the family 
history described below. 
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 FAMILY HISTORY 
Following elements in the patient history should be taken into account when making a judgment if the woman is at high risk, but there remains room for clinical 
judgement: 
 
Individuals with an informative family are considered at high risk for hereditary breast cancer because in the family there are: 
 two first-degree or second-degree relatives from the same side of the family diagnosed with breast cancer at younger age than the average age of 50 
years of the relatives concerned (at least one must be a first-degree relative),  
OR 
 three first-degree or second-degree relatives from the same side of the family diagnosed with breast cancer at younger age than the average age of 60 
years of the relatives concerned (at least one must be a first-degree relative),  
OR  
 four relatives from the same side of the family diagnosed with breast cancer at any age (at least one must be a first-degree relative). 
However, not all families will prove informative. In these cases the threshold for testing is to be considered on a case by case basis after the initial 
assessment at a centre of human genetics specialized in cancer genetics. 
 
Clinicians should seek further advice from a specialist cancer genetics service for individuals in families containing any of the following, in addition 
to breast cancer:   
 ethnic groups with founder mutations, 
 bilateral breast cancer, 
 male breast cancer, 
 ovarian cancer, 
 sarcoma in a relative younger than 45 years of age, 
 glioma or childhood adrenal cortical carcinomas, 
 complicated patterns of multiple cancers at a young age, 
 triple negative breast cancer under the age of 60 years. 
 
Clinicians should also consider to refer their patients to a centre of human genetics specialized in cancer genetics in case of: 
 breast cancer at very young age (< 35 years), 
 epithelial ovarian cancer, 
 pancreatic cancer and two first-degree relatives with pancreatic or ovarian or breast cancer.  
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 ADDITIONAL RECOMMENDATIONS  
 Women with a high breast cancer risk based on the above mentioned criteria should be offered individual risk assessment in order to give individual advice 
on screening strategy, genetic tests and prophylactic measures. Individual risk assessment should be done by professionals with sufficient skills and 
experience, and should include extensive counselling and sufficient attention to patient preferences and support.  
 Use of prediction models can be considered. 
 When using a formal carrier prediction model, a cut-off point for the BRCA1/BRCA2 mutation carrier probability of 5 to 10% can be used. If a prediction 
model is used than 5% is the lower limit for testing and otherwise the BeSHG criteria should be used (see 'Guidelines for hereditary breast and/or ovarian 
cancer syndrome diagnostic testing criteria' of the College for Medical Geneticists available at http://www.beshg.be). 
 If there are problems with using or interpreting carrier probability calculation methods, refer to the testing criteria 'Guidelines for hereditary breast and/or 
ovarian cancer syndrome diagnostic testing criteria' of the College for Medical Geneticists to support your decision (available at http://www.beshg.be). 
 No recommendations can be formulated concerning testing for low- and moderate-penetrance genes in routine clinical practice, as there is still debate on 
the clinical implications of those tests. Future data, however, may yield more insights into the clinical utility of testing for additional breast cancer 
predisposing genes. In this context, PALB2 was recently identified to have a penetrance that could be up to as high as BRCA2 in recent birth cohorts.11 
 
 FOLLOW-UP OF WOMEN AT HIGH RISK 
 For women at proven high risk for breast cancer, yearly MRI is recommended from the age of 25 years onwards. 
 Screening mammography should be used with prudence between 30 and 40 years and not before age 30. 
 For women with a proven BRCA1 or BRCA2 mutation (or a similarly high risk, based on other information) and who opt for screening rather than for 
prophylactic bilateral mastectomy, yearly MRI and yearly mammography with an interval of six months between both examinations can be used from the 
age of 40 years onwards. 
 Ultrasound is useful to reduce the number of false positives when MRI is difficult to interpret. 
 
3.2 Li-Fraumeni syndrome 
3.2.1 Introduction 
Li-Fraumeni syndrome (LFS) is an autosomal dominant cancer syndrome 
caused by heterozygous germline mutations in the TP53 gene. Half of the 
patients with LFS develop at least one LFS-associated cancer by age 30. 
While many tumor types can be seen in patients with LFS, four core cancers 
(breast, sarcoma, brain, and adrenocortical carcinoma) make up about 80% 
of LFS associated tumours.22 The next most frequently associated cancers 
include leukemia, lung, colorectal, skin, gastric, and ovarian.  
 
 
All cancer types are diagnosed at younger than average ages. Moreover, 
LFS predisposes to radiation-induced malignancies as well, therefore use of 
radiology should be limited. It is a rare syndrome, e.g. in The Netherlands 
only 24 families were identified in 2009.23 Approximately 400 families were 
reported in the cumulative literature, but its actual population incidence is 
unknown.24  
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3.2.2 Diagnostic testing criteria for Li-Fraumeni syndrome 
Several sets of criteria have been developed over the past 20 years to help 
identify individuals with LFS who should be considered for TP53 testing. The 
first formal set of criteria developed in 1988 is the Classic LFS criteria; these 
criteria are the most stringent and are the ones used to make a clinical 
diagnosis of LFS (with or without the identification of a deleterious germline 
TP53 mutation).25 Later, broader criteria were developed by Birch and Eeles 
to identify families which are Li-Fraumeni-like (LFL).26, 27 Chompret and 
colleagues developed another set of criteria which were shown to provide 
the highest positive predictive value and, when combined with the classic 
LFS criteria, provided the highest sensitivity for identifying individuals with 
LFS.28 
We only identified one guideline that specifically dealt with testing criteria, 
i.e. the NCCN guideline. Although the NCCN guideline did not have reported 
a formal search strategy, it proposed criteria that are widely adopted. 
Authors proposed to test persons either fulfilling what is called the ‘classic’ 
Li-Fraumeni criteria, and the modified Chompret criteria.28, 29 Criteria were 
also proposed by Birch et al. (1994)26 and Eeles et al. (1995)27 often referred 
to as the ‘Li-Fraumeni like’ criteria. All are based on limited case series. The 
precise criteria are summarized in Appendix 6. 
We looked for studies validating these criteria. Our search strategy is 
detailed in Appendix 2.3. No independent validation study of the testing 
criteria in unselected patients was found. There were some testing studies 
in series in preselected patients. 
Ruijs et al. (2010)30 selected 180 Dutch families referred for TP53 mutation 
analysis based largely on LFS, Li-Fraumeni-like (LFL) and Chompret 
criteria. A TP53 germline mutation was identified in 24 families. When the 
Chompret criteria were used 22/24 mutations were detected (sensitivity 
92%, mutation detection rate 21%). In LFS and LFL families, 18/24 
mutations were found (sensitivity 75%). The two mutations detected outside 
the 'Chompret group' were found in a child with rhabdomyosarcoma and a 
young woman with breast cancer. 
Mitchell et al. (2013)31 tested  a clinic-based, prospective cohort of 559 adult-
onset sarcoma cases, who were screened for mutations in TP53 without 
regard to family history and where 17 germline mutations were found, of 
whom only 10 met classical or Chompret criteria. 
NCCN recommended testing for women with breast cancer under 35. 
However, evidence underpinning this recommendation is conflicting. Lalloo 
et al. (2003)32 aimed to estimate the degree to which BRCA1, BRCA2 and 
TP53 contribute to early-onset breast cancer (age ≤30 years) and to 
establish use of family history in identification of mutation carriers. They  
tested 100 women diagnosed with breast cancer under age 30 for mutations 
in the BRCA1, BRCA2 and TP53 genes and found 2 TP53 mutations in 36 
early onset (< 30 years) breast cancer women with a familial history. Both 
mutations were noted within families that fulfilled criteria for Li-Fraumeni and 
Li-Fraumeni-like syndrome. The high relative risk (>100) of breast cancer in 
women younger than 31 years led authors to recommend that TP53 be 
considered in very young breast-cancer patients (<30 years). 
Rath et al. (2013)33 tested 213 women with primary invasive HER2+ breast 
cancer age <50 years from a single centre and found 3 TP53 mutations 
(ages at diagnosis 23, 32, 44 years; 1.4%, 95% CI 0.3-4.1%). 
Lee et al. (2012)34 identified 4 clinically relevant TP53 mutations when 
testing 100 patients with early onset breast cancer, of whom 83 BRCA 
negative, 3 of the 4 fulfilled the LFS criteria. 
Penkert et al. (2011)35 tested 62 BRCA1/BRCA2-negative women from 
families fulfilling the criteria for hereditary breast and ovarian cancer. Among 
them, 22 women had early onset breast cancer, diagnosed at or before the 
age of 34 years (range 22 to 34 years). Of all, 31 women fulfilled Chompret 
(8) Li-Fraumeni criteria or Eeles/Birch (23) Li-Fraumeni-like criteria but did 
not detect TP53 mutations nor TP53 large genomic rearrangements. 
Nevertheless, there are no studies that have directly addressed what the 
additional yield in detection of TP53 mutation carriers is when an age cut-off 
of 35 years is applied compared to an age cut-off of 30 years (or, in other 
words, what number of patients with a TP53 mutation would be missed when 
the age threshold is lowered from 35 yrs to 30 yrs). As there are no large 
studies that have directly addressed this issue, the decision on the age 
threshold can only be based on “expert opinion”. 
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3.2.3 Follow-up of patients with Li-Fraumeni syndrome 
NICE provided specific recommendations for the follow-up of patients with 
clinically relevant TP53 germline mutations.  
It recommended to consider annual MRI surveillance for women aged 20–
69 years with a known TP53 mutation. This recommendation is based on 
evidence in women at high risk of breast cancer in general. It recommended 
not to do mammography in this group, essentially based on theoretical risk 
of malignancy due to the higher susceptibility of TP53 women to radiation. 
We did not identify primary studies related to breast cancer surveillance and 
screening in women with TP53 germline mutations.  
However, we found one observational study by Villain et al. (2011)36 where 
33 TP53 mutation carriers were identified, 18 of whom underwent 
comprehensive cancer surveillance. The surveillance protocol detected ten 
asymptomatic tumours in seven patients. Median follow-up was 24 months 
(IQR 22-65 months). Twelve high-grade, high-stage tumours developed in 
10 individuals in the non-surveillance group, of whom 2 (20%) were alive at 
the end of the follow-up (p=0.0417 for comparison with survival in the 
surveillance group). Three-year overall survival was 100% in the 
surveillance group and 21% (95% CI 4-48%) in the non-surveillance group 
(p=0.0155). However, clinical implications of this study are unclear, as 
follow-up time was too short to take into account lead time bias. It is also 
unclear if confounding was sufficiently addressed. 
O’ Neil et al. (2013)37 screened 15 pediatric LFS patients with whole-body 
MRI (WB-MRI) twice annually but the study only demonstrated feasibility, 
follow-up time being too short to demonstrate effects on survival. 
Masciari et al. (2008)38 identified 3 asymptomatic cancer in 15 LFS patients 
using F18-fluorodeoxyglucose–positron emission tomography/computed 
tomography (FDG-PET/CT); clinical implications of these findings and effect 
on mortality or morbidity remain unclear. 
Conclusions 
 Evidence for testing criteria is limited 
 Evidence for surveillance for breast cancer is extrapolated from 
evidence for surveillance among women at high risk for breast cancer in 
general 
 There is some evidence that TP53 women may be more susceptible to 
radiation than others 
 There is no evidence for surveillance for other cancers 
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Other considerations  
Factor Comment 
Balance between clinical benefits and 
harms 
In the Belgian clinical practice, geneticists see quite some patients with breast cancer between 30 years and 35 
years but very rarely encounter mutations in the TP53 gene. Testing strategies differ between centres but relied on 
family history and BRCA1/BRCA2 mutation. The following strategy was suggested: ‘In a breast cancer patient 
younger than 30 years negative for a BRCA1 or BRCA2 mutation, offer TP53 testing. In a breast cancer patient 
between 30 and 35 years with a normal BRCA1 and BRCA2 result, do not systematically offer TP53 testing; TP53 
testing can be considered if there is a strong family history of breast cancer or other cancers that belong to the 
spectrum of the Li-Fraumeni syndrome (which probably results in a very small absolute risk of missing a de novo 
TP53 mutation)’. 
There is no proven benefit of preventive measures, therefore testing for Li-Fraumeni should only be done after 
extensive counselling and should only be offered under limited conditions. 
Quality of evidence  Li-Fraumeni is a rare disease. Criteria for testing are put forward but the disease is too rare to formally validate 
models.   
 For surveillance and follow-up, there are only limited data.   
 There is indirect proof that carriers are more sensitive to radiation, therefore the GDG does not recommend 
mammography in this group. 
Costs (resource allocation) Because TP53 is rare, testing should only be offered to patients that fullfill strict criteria, Classic Li-Fraumeni 
Syndrome, Li-Fraumeni Like Syndrome or the revised Chompret criteria. This way, cost is likely to remain 
acceptable. 
Patients values and preferences Patients’ representatives ask that a correct and understandable information be provided to individuals at increased 
genetic risk. A dedicated support in decision-making is important for the different phases of the process (referral, 
testing, steps after a positive or a negative test). It is important to clearly explain figures about the increased risk of 
(breast/ovarian) cancer. 
Balanced and understandable information about the pros and cons of the various decisions has to be provided (e.g. 
about surveillance by mammography).  
There's a need for good psychosocial support (by professionals and by fellow patients) when making choices, when 
informing children and family members about the genetic predisposition or with respect to fertility planning. 
A uniform policy followed by all Genetic Centres in Belgium is essential. 
It is important that general practitioners / oncologists / gynaecologists / psychologists are well informed (or trained) 
about genetic mutations. Currently, a lot of people are not referred or do not receive the correct information about 
various mutations due to a lack of knowledge of these professionals. 
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Recommendations 
 DIAGNOSTIC TESTING CRITERIA 
A person should be only offered counseling and genetic testing if he or she fulfills either the criteria for Classic Li-Fraumeni Syndrome, Li-Fraumeni Like 
Syndrome or the revised Chompret criteria, or for early onset breast cancer. 
Classic Li-Fraumeni Syndrome (LFS) 
 A proband with a sarcoma diagnosed before age 45 years,  
AND 
 A first-degree relative with any cancer before age 45 years,  
AND 
 A first- or second-degree relative with any cancer before age 45 years or a sarcoma at any age. 
 
Li-Fraumeni Like Syndrome 
Birch definition: 
 A proband with any childhood cancer OR with sarcoma, brain tumour, or adrenocortical carcinoma diagnosed before age 45 years,  
AND 
 A first- or second-degree relative with a typical LFS cancer (sarcoma, breast cancer, brain tumor, adrenocortical carcinoma, or leukemia) at any age, 
AND 
 A first- or second-degree relative with any cancer before age 60 years 
Eeles definition: 
 Two first- or second-degree relatives with LFS-related malignancies at any age. 
Chompret criteria  
 A proband with a tumour belonging to the LFS tumor spectrum (soft tissue sarcoma, osteosarcoma, brain tumour, pre-menopausal breast cancer, 
adrenocortical carcinoma, leukemia, or bronchoalveolar lung cancer) before age 46 years, AND at least one first- or second-degree relative with an LFS 
tumour (except breast cancer if the proband has breast cancer) before age 56 years or with multiple tumours,  
OR 
 A proband with multiple tumours (except multiple breast tumours), two of which belong to the LFS tumour spectrum and the first of which occurred before 
age 46,  
OR 
 A proband who is diagnosed with adrenocortical carcinoma or choroid plexus tumour, irrespective of family history 
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Early onset breast cancer 
 For individual with breast cancer ≤30 years with a negative BRCA1/BRCA2 test, offer a TP53 test 
 
 ADDITIONAL RECOMMENDATIONS 
 Individual risk assessment should be done by professionals with sufficient skills and experience, and should include extensive counselling and sufficient 
attention to patient preferences and support. 
 Discuss with the patient the possibility to perform prophylactic bilateral mastectomy. However, the patient should be informed that there is no proof that 
preventive measures have a benefit overall. 
 
 FOLLOW-UP OF WOMEN AT HIGH RISK  
 For women with a proven TP53 mutation who opt for screening rather than for prophylactic bilateral mastectomy, yearly MRI is recommended from the 
age of 25 years onwards.   
 Yearly mammography is not recommended because of the higher susceptibility to radiation. 
 Ultrasound is useful to reduce the number of false positives when MRI is difficult to interpret. 
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3.3 Cowden syndrome or PTEN hamartoma tumour 
syndrome (PHTS) 
3.3.1 Introduction 
The following general description of the disease is literally taken from 
Pilarski et al.23 ‘The term PTEN hamartoma tumour syndrome (PHTS) has 
been used to refer to a spectrum of disorders that have been linked to 
germline mutations in the phosphatase and tensin homolog (PTEN) gene, 
including Cowden syndrome (CS), Bannayan-Riley-Ruvalcaba syndrome 
(BRRS), adult Lhermitte-Duclos disease (LDD), and autism spectrum 
disorders associated with macrocephaly. The bulk of the clinical data on 
these disorders comes from studies of patients with Cowden syndrome, and 
less commonly BRRS.  
Cowden Syndrome is a rare, multisystem disease that causes increased 
risks for malignancies (breast, thyroid, and endometrial) as well as benign 
hamartomatous overgrowth of tissues (skin, colon, thyroid, etc).  
CS was first described in one family in 1963 and then extended by Weary et 
al. who added an additional set of 5 patients and expanded the spectrum of 
component features.’ Cowden syndrome has a prevalence of about 1 in 
250 000 in the Dutch population with a low mutation frequency.39 
3.3.2 Diagnostic testing criteria and diagnostic criteria for Cowden 
syndrome. 
‘Diagnostic criteria for CS were initially proposed by Salem and Steck in 
198340 and later revised by consensus of an international consortium of 
researchers in 1996 before identification of the CS gene.41 Clinical 
diagnoses since that time have been based on these consortium criteria, 
which were based upon early clinical experience and compilations of cases 
published in the literature, with their inherent selection biases, rather than 
on unselected series of patients.’23  Criteria have been updated in 2000 and 
2004.42, 43 Finally, Pilarski et al.44 proposed a new modification of the criteria 
based upon a systematic review and expert opinion (see Appendix 7). Note 
however that these are diagnostic criteria, not diagnostic testing criteria. 
We only identified one guideline that specifically dealt with testing criteria, 
i.e. the NCCN guideline. Although the NCCN guideline did not report a 
formal search strategy, the criteria proposed by NCCN are widely adopted. 
NCCN based these criteria largely on consortium criteria combined with 
expert opinion and the results of 2 large cohort studies45, 46 (testing criteria 
are displayed in Appendix 8).   
We searched for cohort studies or transversal studies that assessed 
predictive values for a positive PTEN test and identified 2 cohort studies, 
already mentioned in the NCCN paper, that assessed prediction criteria in a 
prospective way.  
Pilarski et al.21 reviewed molecular and clinical data on 802 patients referred 
for PTEN analysis in the Ohio State University cohort and found deleterious 
mutations in 172 (21.4%) subjects. Among mutation carriers, significant 
differences from previous reports were found for the frequencies of several 
clinical features, including macrocephaly, uterine fibroids, benign breast 
disease and endometrial cancer. Logistic regression analyses indicated that 
female mutation carriers were best identified by the presence of 
macrocephaly, endometrial cancer, trichilemmomas, papillomatous 
papules, breast cancer, benign thyroid disease, and benign gastrointestinal 
(GI) lesions. For males, the most discriminating features were 
macrocephaly, lipomas, papillomatous papules, penile freckling, benign GI 
lesions, and benign thyroid disease. Age related differences were also 
identified. They found that the mutation frequency in patients meeting CS 
diagnostic criteria (34%) was significantly lower than previously reported. 
Based on this study, they also proposed a PTEN risk prediction calculator. 
Tan et al. (2011)45 conducted a multicenter prospective study including two 
independent cohorts (the Cleveland Clinic cohort and the Ohio State 
University cohort) in which 3 042 probands satisfied relaxed International 
Cowden Consortium operational criteria for CS (pathognomonic criteria, or 
at least two criteria, either major or minor, see also Appendix 7). PTEN 
mutation scanning, including promoter and large deletion analysis, was 
performed for all subjects. Pathogenic mutations were identified in 290 
individuals (9.5%). Based on the data of these cohort studies, the authors 
derived a clinical score system for adults and clinical criteria for children, 
using complex modeling and the data from the Cleveland Clinic cohort. They 
then validated the score system and the criteria on the data from the Ohio 
State University cohort. They fixed a threshold using ROC analysis for the 
clinical score system and assessed the calibration with bootstrap validation 
that yielded an optimism-corrected concordance index of 0.91.  
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No independent validation of these criteria and score was done until now. 
Note that both cohorts concern patients in referral academic centres and 
selected based on the relaxed Cowden criteria, in themselves expert opinion 
based. This implies a double pre-selection of that patient group where the 
models were tested, and the results only apply to a population selected in 
this way. This is a population that is likely to differ in important ways from 
the population presenting to a typical Belgian centre for genetic testing and 
counseling, and it is unclear to what degree they are valid in the Belgian 
context. 
3.3.3 Follow-up of patients with Cowden syndrome 
As could be expected, given the rareness of the syndrome we did not find 
any studies that assessed the effectiveness of screening nor sensitivity and 
specificity of screening algorithms in this specific group. 
We selected studies with the following inclusion criteria in order to have an 
idea of the cumulative cancer risk in this group: non-comparative cohort 
studies or case series that recruited patients in a consecutive way. 
We found 5 studies assessing the cumulative risk for different cancers. 
Details of the studies are given in the evidence tables. 
Tan et al. (2012)47 prospectively recruited 3 399 individuals meeting relaxed 
International Cowden Consortium PHTS criteria and found 368 individuals 
with deleterious germline PTEN mutations. Estimated lifetime risks were for 
cancers of the breast: 85.2% (95% CI, 71.4%–99.1%), thyroid 35.2% 
(19.7%–50.7%), endometrium 28.2% (17.1%–39.3%), colorectum 9.0% 
(3.8%–14.1%), kidney 33.6% (10.4%–56.9%) and finally melanoma 6% 
(1.6%-9.4%). 
Bubien et al. (2013),40 van Nieuwenhuis (2012),42, 48 Heald et al. (2010)41 
reported similar results (more details are reported in Appendix 8.1). 
Riegert-Johnson (2010)43 reported cumulative rates for patients with 
Cowden syndrome, either with PTEN pathogenic germline mutations or not 
and found similar results. 
We did not find studies assessing the effects of screening for different 
cancers in this group, it is however unlikely that such studies will ever be 
conducted due to the rare nature of the disease.  
 
Conclusions 
 Evidence for testing criteria is limited. 
 Evidence for surveillance for breast cancer is extrapolated from 
evidence for surveillance among women at high risk for breast cancer in 
general. 
 There is evidence for an increased risk of breast cancer, endometrium 
cancer, renal and thyroid cancer but there is no evidence of the 
effectiveness of screening for those conditions. 
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Other considerations  
Factor Comment 
Quality of evidence on the balance 
between clinical benefits and harms
Criteria are largely consensus based. Some predictive computer carrier prediction models are developed but not 
sufficiently validated. 
Due to the rareness of the disease there are only limited data on effectiveness of preliminary screening but there are 
credible studies on lifetime risk. 
Therefore the recommendations for breast cancer surveillance are based on the general evidence for BRCA patients, 
as GDG judged it sufficiently comparable. 
The recommendation on thyroid screening is consensus based. Elevated risk for thyroid cancer is proven, benefit of 
the screening not. 
Costs (resource allocation) Because PTEN is rare, testing should only be offered to patients that fullfill strict criteria.  This way, cost is likely to 
remain acceptable. 
Patients values and preferences Patients’ representatives ask that a correct and understandable information be provided to individuals at increased 
genetic risk. A dedicated support in decision-making is important for the different phases of the process (referral, 
testing, steps after a positive or a negative test). It is important to clearly explain figures about the increased risk of 
(breast/ovarian) cancer. 
Balanced and understandable information about the pros and cons of the various decisions has to be provided (e.g. 
about surveillance by mammography).  
There's a need for good psychosocial support (by professionals and by fellow patients) when making choices, when 
informing children and family members about the genetic predisposition or with respect to fertility planning. 
A uniform policy followed by all Genetic Centres in Belgium is essential. 
It is important that general practitioners / oncologists / gynaecologists / psychologists are well informed (or trained) 
about genetic mutations. Currently, a lot of people are not referred or do not receive the correct information about 
various mutations due to a lack of knowledge of these professionals. 
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Recommendations 
 DIAGNOSTIC TESTING CRITERIA (NCCN TESTING CRITERIA) 
The following testing criteria should be considered when deciding for counselling, genetic testing and follow-up: 
 
Cowden Syndrome PTEN Gene Testing Criteria 
Individual from a family with a known PTEN gene mutation; 
Individual meeting clinical diagnostic criteria for Cowden Syndrome; 
Individual with a personal history of: 
 Bannayan-Riley-Ruvalcaba syndrome (BRRS) OR 
 Adult Lhermitte-Duclos disease (cerebellar tumours) OR 
 Autism spectrum disorder and macrocephaly OR 
 Two or more biopsy-proven trichilemmomas OR 
 Two or more major criteria* (one must be macrocephaly) OR 
 Three major criteria*, without macrocephaly OR 
 One major* and ≥ three minor criteria** OR 
 ≥ Four minor criteria** 
 
At-risk individual with a relative with a clinical diagnosis of Cowden syndrome or BRRS for whom testing has not been performed 
 The at-risk individual must have the following: 
o Any one major criterion* OR 
o Two minor criteria** 
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* Major criteria: 
 Breast cancer 
 Endometrial cancer 
 Follicular thyroid cancer 
 Multiple gastrointestinal hamartomas or ganglioneuromas 
 Macrocephaly  
 Macular pigmentation of glans penis (a discolored area on the skin) 
 Mucocutaneous lesions 
o One biopsy proven trichilemmoma 
o Multiple palmoplantar keratoses (abnormal thickening of the hands and feet) 
o Multifocal or extensive oral mucosal papillomatosis 
o Multiple cutaneous facial papules (often verrucous) 
 
** Minor Criteria: 
 Autism spectrum disorder 
 Colon cancer 
 Esophageal glycogenic acanthosis (≥3) 
 Mental retardation (i.e. IQ<75) 
 Papillary or follicular variant of papillary thyroid cancer 
 Thyroid structural lesions (such as adenoma, nodule(s), goiter) 
 Renal cell carcinoma 
 Vascular anomalies (including multiple intracranial developmental venous anomalies) 
 Lipomas (benign soft tissue tumour) 
 Single gastrointestinal hamartoma or ganglioneuroma 
 Testicular lipomatosis 
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 FOLLOW-UP OF WOMEN AT HIGH RISK 
The efficacy, risk, and benefits of cancer screening in Cowden syndrome are unknown.24 Recommendations listed below are suggested in the 
scientific literature and were based on expert opinions. 
 
 For women with a proven PTEN mutation who opt for screening rather than for prophylactic bilateral mastectomy, yearly MRI is recommended from the 
age of 25 years onwards. From the age of 40 years onwards, yearly MRI and yearly mammography with an interval of six months between both 
examinations can be used 
 Mammography should be used with prudence between 30 and 40 years but should not be used before age 30. 
 Ultrasound is useful to reduce the number of false positives when MRI is difficult to interpret. 
 No studies have assessed efficacy of prophylactic mastectomy in Cowden Syndrome. Without recommending such intervention, healthcare professionals 
can discuss with each patient the balance benefits/harms of preventive surgery (risk-reducing mastectomy) and counsel regarding degree of protection, 
extent of cancer risk and reconstruction options.21 
 Annual screening with ultrasound of the thyroid gland could be considered, starting at age 18 y.24 
 Because data regarding lifetime risk of endometrial cancer are limited, surveillance screening (ultrasound and/or endometrial biopsy has been suggested 
to begin at age 35–40 or 5 years before the earliest endometrial cancer in the family)24 and surgical intervention (hysterectomy) should be on an individual 
basis. 
 Colonoscopy can be considered, starting at age 35 y, then every 5-10 y or more frequently if patient is symptomatic or polyps were found.21 
 If there is a family history of renal cell cancer, an annual urinalysis has been suggested, supplemented by cytology and renal ultrasound.24 
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5 IMPLEMENTATION AND UPDATING OF 
THE GUIDELINE 
5.1 Implementation 
5.1.1 Multidisciplinary approach 
In this report we focused on the effectiveness of specific diagnostic 
interventions. In clinical practice, a multidisciplinary approach by different 
health care professionals should be encouraged. This approach should not 
only cover the medical needs of the patients but also their psychosocial 
needs. 
5.1.2 Patient-centered care 
The choice of an intervention, e.g. germline mutation analysis, should not 
only consider medical aspects but also patient preferences. Patients’ 
representatives ask that a correct and understandable information be 
provided to individuals at increased genetic risk. Continued support in 
decision-making is important during the different phases of the process 
(referral, testing, steps after a positive or a negative test). It is important to 
clearly explain figures about the increased risk of (breast/ovarian) cancer. 
Balanced and understandable information about the pros and cons of the 
various decisions has to be provided (e.g. about surveillance by 
mammography). There is a need for psychosocial support (by professionals 
and by fellow patients) when making choices, when informing children and 
family members about the genetic predisposition or with respect to fertility 
planning. A uniform policy followed by all Genetic Centres in Belgium is 
essential. It is important that general practitioners / oncologists / 
gynaecologists / psychologists are well informed about genetic mutations. 
According to the patients’ representatives, a lot of people are currently not 
referred or do not receive the correct information about various mutations 
due to a lack of knowledge of these professionals. 
5.1.3 Barriers and facilitators for implementation of this guideline 
Some medical oncologists would prefer to be able to offer the pre-test 
counselling and the genetic testing themselves and immediately, instead of 
referring their patient to a centre of human genetics specialized in cancer 
genetics for genetic counselling. They also claim that sometimes losing 
precious time is thus lost before an appropriate treatment is started. 
Geneticists feel it is absolutely required to refer individuals/patients to a 
centre of human genetics specialized in cancer genetics for counselling and 
testing rather than ordering a genetic test directly. This stepwise approach 
allow patients to benefit from specific tests prescribed by specialists in 
genetics, but also to benefit from genetic counselling about the risks, 
benefits and consequences of testing. A specific comprehensive 
consultation “genetic counselling” is reimbursed by INAMI/RIZIV for this 
purpose. Such consultation includes personal and family history taking, the 
search for information on family cases, the selection of the most appropriate 
tests to assess the individual risk of developing the disease, the information 
about the tests characteristics, the results of the test performed about the 
individual personal risk, the measures to prevent or detect the disease as 
early as possible. Following the legislation on breast cancer clinics (AR/KB 
26.04.2007), coordinating breast cancer clinics have to sign a written 
agreement with a centre of human genetics to organize a genetic 
consultation for patients. 
Numerous barriers to refer individuals at risk of cancer to outside cancer 
genetics have been summarized by Prochniak et al. (2012),49 including: lack 
of knowledge regarding who should be referred; doubts about the clinical 
utility of genetic testing; and concerns regarding insurance coverage of 
services, patient confidentiality, and genetic discrimination. In their own 
prospective study,49 these authors found that clinicians who considered their 
role also includes ordering tumour testing, ordering germline testing, and 
interpreting genetic test results and those who felt confident doing so were 
more likely to report they would order their own testing than those who 
preferred to refer patients for testing. Physicians who preferred to refer to 
outside cancer genetics experts were more likely to value the counseling 
provided by outside genetics experts regarding the risks, benefits and 
consequences of the test. Authors recommended to increase referral to 
outside cancer genetics experts by focusing on the unique, evidence-based 
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benefits that genetic counselling provides to patients over and above the 
services received when a physician orders tests independently. 
The identification of potential barriers and facilitators related to the use of 
this guideline is limited to a discussion held during the stakeholders meeting. 
More sophisticated methods could be used, but this would go beyond the 
scope of this project. More information on the identification of barriers and 
facilitators in guidelines implementation can be found in a recent KCE-report 
(see KCE website). 
5.1.4 Actors of the implementation of this guideline 
Clinical guidelines provide a tool for physicians to consult at different stages 
of the patient management pathway: screening, diagnosis, treatment and 
follow-up. They are developed according to highly codified principles, based 
on scientific information regularly updated from the international literature. 
KCE formulates recommendations addressed to specific audiences 
(clinicians, decision-makers, sickness funds, INAMI/RIZIV, professional 
organizations, hospital managers...).  KCE is not involved in the decision 
making process itself, or in the execution of the decisions.  
5.2 Monitoring the quality of care  
This guideline should be considered as a starting point to develop quality 
improvement programs that targets all caregivers concerned.  
It can be used as a tool to support health policies to improve the quality of 
care, e.g. through the support of actions to increase caregivers’ awareness 
and to improve their practice, or through the development (or revision) of 
sets of process and outcome quality indicators.  
The obligatory yearly registrations to the INAMI/RIZIV of genetic testing 
activities (including numbers of cases identified) to the INAMI/RIZIV  (Article 
33) can be a useful source to monitor the activity and a possible impact of 
guideline implementation. 
5.3 Guideline update 
In view of the rapidly evolving evidence due to the dynamic nature of this 
field, especially with regard to current risk estimations (e.g. The upper level 
of the lifetime breast cancer risk estimate associated with PALB2 mutations 
has recently shown to overlap with that for BRCA2), genetic testing 
capabilities, the clinical introduction of the routine analysis of a broad panel 
of germline DNA in at risk subjects will be monitored by the authors and this 
guideline should be updated when sufficient clinical evidence is available. If, 
in the meantime, important new evidence would become available, this 
should be taken into consideration in the medical decision making.   
5.4 Research agenda 
The use of genetic tests in oncology is a very rapidly moving field on many 
fronts. In particular, there is a rapid evolution in the technical capabilities to 
perform multiple genetic tests as a panel. Therefore, the authors will assess 
the clinical impact of gene panels in at risk subjects through results of 
ongoing research studies and regular review of the literature. 
 
In the near future, it will be important to address certain key aspects again. 
In particular these three areas will need to be addressed: 
1. Validation of mutation prediction models in the Belgian population. 
2. Scope of testing for moderate penetrance genes in the context of Next 
Generation Sequencing panels 
3. Plan for integrating genetic testing into oncological practice. 
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■ APPENDICES 
APPENDIX 1. GDG MEMBERS 
Institution/Organisation Professional 
Specialty 
First Name Name 
UCL Medical oncologist Martine Berlière 
UGent Molecular geneticist Kathleen Claes 
UCL Clinical geneticist Nicolas Janin 
UZ Leuven Molecular geneticist Gert Matthijs 
UGent Clinical geneticist Bruce Poppe* 
Institut Jules Bordet Medical oncologist Daphné ‘t Kint de Roodenbeke 
UGent Clinical geneticist Tom Van Maerken** 
UZ Leuven Medical oncologist Hans Wildiers 
Note. * President GDG; ** Vice-President GDG 
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APPENDIX 2. SEARCH STRATEGIES 
Appendix 2.1. Hereditary breast cancer 
PICO 
Project number 2013-51 
Project name Oncogenetic testing 
Search 
question(s)   
Systematic reviews about genetic testing in the case of breast neoplasms. 
Structured search question(s) (PICO, SPICE, 
ECLIPSE, ..)  
and related keywords 
A Breast Breast/ 
Breast? 
Mammary 
Breast.jn 
Breast Care.jn 
 
A&B 
Breast Neoplasms/ 
B Cancer Neoplasms/ 
 
KEYWORDS 
Neoplasm? 
Cancer* 
Malign* 
Tumor* 
Tumour* 
Carcinoma* 
Adenocarcinom* 
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Metastat* 
Metastas* 
Oncolog* 
 
B&C 
Neoplastic syndromes, hereditary/ 
Clinical Breast Cancer.jn 
Breast Cancer Research & Treatment.jn 
Breast Cancer Research.jn 
Breast Cancer.jn 
Journal of Breast Cancer.jn 
International Journal of Breast Cancer.jn 
C Genetic Genes, BRCA1/ 
Genes, BRCA2/ 
Genetic Predisposition to Disease/ 
Mutation/ 
Genetic counseling/ 
Genetic markers/ 
Polymorphism, genetic/ 
Polymorphism, single stranded conformational/ 
Genetic phenomena/ 
Genes/ 
 
B&C 
DNA, neoplasm/ 
 
C&D 
Genetic Testing/ 
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KEYWORDS 
heredit* 
inherit* 
famil* 
counsel* 
mutation? 
gene? 
Genet* 
Pharmacogenet* 
Genom* 
Allele? 
Genotyp* 
Phenotyp* 
Polymorphism? 
Molecular 
Transcript* 
DNA 
RNA 
Chromosom* 
Carrier? 
Counselling 
Predisposition? 
BRCA1 
BRCA2 
TP53 
STKII 
STK2 
PTEN 
CHEK2 
PALB2 
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BRIP1 
LKB1 
D Testing exp Microarray Analysis/ 
exp Mass Screening/ 
 
Risk assessment/ 
Disease susceptibility/ 
 
KEYWORDS 
Screened, screening, sequencing, phenotyping, genotyping, detecting, detection, test, tests, 
testing, profile, profiling 
Assess* 
Analys* 
Analyz* 
Identif* 
Determin* 
Find 
Diagnos* 
Detect* 
Prevalen* 
 
Possibly: 
(Risk/ OR Risk Factors/) 
AND 
(KEYWORDS) 
S (settings) Systematic Review  
STRATEGY  (((A & B) OR AB) & C) OR (A & BC)) 
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Appendix 2.1.1. Medline @ Ovid 
Date 2014-02-05 
Database  Medline (OVID) 
Search Strategy 
(attention, for PubMed, 
check « Details ») 
# Query Results 
1 exp Breast/  30786 
2 breast*.tw,kw,kf.  294163 
3 mammary.tw,kw,kf.  57836 
4 1 or 2 or 3  338970 
5 exp Neoplasms/  2485943 
6 tumor*.tw,kw,kf.  949418 
7 tumour*.tw,kw,kf.  201274 
8 cancer*.tw,kf,kw.  1049967 
9 oncolog*.tw,kf,kw.  78909 
10 metastas*.tw,kw,kf.  220957 
11 carcinom*.tw,kw,kf.  467290 
12 malign*.tw,kf,kw.  396099 
13 adenocarinom*.tw,kf,kw.  31 
14 neoplas*.tw,kw,kf.  279245 
15 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14  2235125 
16 5 or 15  3014977 
17 4 and 16  260966 
18 exp Breast neoplasms/  209684 
19 17 or 18  290776 
20 exp Genetic Predisposition to Disease/  84570 
21 exp Genetics/  168290 
22 exp Genetic markers/  44142 
23 exp Polymorphism, genetic/  187939 
24 exp Polymorphism, single stranded conformational/  10287 
25 20 or 21 or 22 or 23 or 24  413726 
26 screening.tw,kw,kf.  318511 
27 screened.kw,kf,tw.  91374 
28 testing.tw,kw,kf.  333272 
29 tests.tw,kw,kf.  461505 
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30 test.tw,kw,kf.  949925 
31 tested.tw,kw,kf.  646389 
32 profil*.tw,kw,kf.  449685 
33 26 or 27 or 28 or 29 or 30 or 31 or 32  2624902 
34 di.xs.  4283067 
35 diagnosis.tw,kw,kf.  1053771 
36 detection.kw,tw,kf.  572192 
37 34 or 35 or 36  4988978 
38 37 and 25  82741 
39 exp Genetic testing/  25183 
40 exp genetic counseling/  11541 
41 exp DNA mutational analysis/  45000 
42 exp Heterozygote Detection/  7957 
43 exp Genetic Techniques/  1457684 
44 exp Microarray Analysis/  70728 
45 39 or 40 or 41 or 42 or 43 or 44  1469220 
46 (genet* adj3 (test* or screened or screening or detect* or assess* or profil* or 
counsel?ing)).tw,kw.  
42970 
47 ((proteom* or genom* or gene? or sequence?) adj3 (screening or profil* or sequencing or 
screening or screened)).tw,kw.  
67854 
48 (expression adj3 profil*).tw,kw.  46324 
49 46 or 47 or 48  129290 
50 38 or 45 or 49  1553868 
51 exp Mass Screening/  97361 
52 exp population surveillance/  48444 
53 51 or 52  143619 
54 33 or 53  2689779 
55 25 and 54  91693 
56 50 or 55  1580032 
57 19 and 56  39449 
58 exp breast neoplasms/ge  30655 
59 exp Genes, BRCA1/  4594 
60 exp Genes, BRCA2/  2691 
61 58 or 59 or 60  32204 
62 exp breast neoplasms/di  25837 
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63 50 or 54 or 62  3913407 
64 61 and 63  21063 
65 exp Neoplasms/ge  274050 
66 exp Neoplastic syndromes, hereditary/  41069 
67 ((hereditary or famil* or genetic* or inherited) adj3 (cancer? or tumo?r* or neoplasm* or 
carcinom* or adenocarcinom*)).tw,kw.  
31213 
68 65 or 66 or 67  310939 
69 68 and 4  38229 
70 54 or 50  3896912 
71 69 and 70  23571 
72 57 or 64 or 71  43183 
73 limit 72 to systematic reviews  623 
74 gene?.tw,kw.  1391683 
75 genetic.tw,kw.  531502 
76 genetics.tw,kw.  69783 
77 mutation?.tw,kw.  411744 
78 allele?.tw,kw.  157196 
79 BRCA*.tw,kw.  10812 
80 TP53.tw,kw.  5201 
81 STK2.tw,kw.  10 
82 STKII.tw,kw.  1 
83 CHEK2.tw,kw.  340 
84 HER2.tw,kw.  10676 
85 ('17q12-21' or '17q12-q21' or '17q12' or '17q21' or '13q12-13' or '13q12-q13' or '13q12-
3').tw,kw.  
1188 
86 "17p13.1".tw,kw.  308 
87 "19p13.3".tw,kw.  300 
88 "22q12.1".tw,kw.  54 
89 "11q22.3".tw,kw.  124 
90 (atm adj2 (gene or locus or loci)).tw,kw.  772 
91 (cdh1 or "16q22.1").tw,kw.  1469 
92 (pten or "10q23.3").tw,kw.  7365 
93 (palb2 or "16p12.1").tw,kw.  230 
94 (bardi or "2q34" or "2q35" or "2q34-q35" or "2q34-35" or "2q34-5").tw,kw.  342 
95 (brip1 or "17q22" or "17q23" or "17q24" or "17q22-q24" or "17q22-24" or "17q22-4").tw,kw.  637 
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96 (mre11a or "11q21").tw,kw.  184 
97 (nbn or "8q21").tw,kw.  378 
98 (rad50 or "5q31").tw,kw.  1672 
99 (rad51c or "17q25.1").tw,kw.  191 
100 (xrcc2 or "7q36.1").tw,kw.  243 
101 (rad51d or "17q11").tw,kw.  270 
102 (abraxas or "4q21.23").tw,kw.  40 
103 74 or 75 or 76 or 77 or 78 or 79 or 80 or 81 or 82 or 83 or 84 or 85 or 86 or 87 or 88 or 89 or 
90 or 91 or 92 or 93 or 94 or 95 or 96 or 97 or 98 or 99 or 100 or 101 or 102  
1896256 
104 assess*.tw,kw.  1692234 
105 detect*.tw,kw.  1579990 
106 sequencing.tw,kw.  128300 
107 33 or 104 or 105 or 106  4988466 
108 (screening.tw,kw,kf. or screened.kw,kf,tw. or testing.tw,kw,kf. or tests.tw,kw,kf. or 
test.tw,kw,kf. or tested.tw,kw,kf. or profil*.tw,kw,kf. or assess*.tw,kw. or detect*.tw,kw. or 
sequencing.tw,kw.) adj3 (gene? or genetic or genetics or mutation? or allele? or BRCA* or 
TP53 or STK2 or STKII or CHEK2 or HER2 or ('17q12-21' or '17q12-q21' or '17q12' or '17q21' 
or '13q12-13' or '13q12-q13' or '13q12-3') or "17p13.1" or "19p13.3" or "22q12.1" or "11q22.3" 
or (atm adj2 (gene or locus or loci)) or (cdh1 or "16q22.1") or (pten or "10q23.3") or (palb2 or 
"16p12.1") or (bardi or "2q34" or "2q35" or "2q34-q35" or "2q34-35" or "2q34-5") or (brip1 or 
"17q22" or "17q23" or "17q24" or "17q22-q24" or "17q22-24" or "17q22-4") or (mre11a or 
"11q21") or (nbn or "8q21") or (rad50 or "5q31") or (rad51c or "17q25.1") or (xrcc2 or "7q36.1") 
or (rad51d or "17q11") or (abraxas or "4q21.23")).tw,kw.  
701895 
109 108 and 19  25195 
110 limit 109 to systematic reviews  593 
111 EndoPredict.tw,kw.  10 
112 PAM50.tw,kw.  50 
113 "Genomic Grade Index".tw,kw.  24 
114 MammaPrint.tw,kw.  101 
115 "oncotype DX".tw,kw.  179 
116 oncotypedx.tw,kw.  18 
117 "Breast Cancer Index".tw,kw.  21 
118 111 or 112 or 113 or 114 or 115 or 116 or 117  320 
119 limit 118 to systematic reviews  16 
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120 (screening.tw,kw,kf. or screened.kw,kf,tw. or testing.tw,kw,kf. or tests.tw,kw,kf. or 
test.tw,kw,kf. or tested.tw,kw,kf. or profil*.tw,kw,kf. or assess*.tw,kw. or detect*.tw,kw. or 
sequencing.tw,kw.) adj3 ((tumor* or tumour*).tw,kw,kf. or cancer*.tw,kf,kw. or 
oncolog*.tw,kf,kw. or metastas*.tw,kw,kf. or carcinom*.tw,kw,kf. or malign*.tw,kf,kw. or 
adenocarinom*.tw,kf,kw. or neoplas*.tw,kw,kf.)  
663769 
121 120 and 4  94503 
122 25 or 45 or 68 or 103  2717634 
123 121 and 122  31447 
124 limit 123 to systematic reviews  679 
125 73 or 110 or 119 or 124  862 
Note    
Appendix 2.1.2. Embase @ Embase.com 
Date 2014-02-05 
Database  Embase (Embase.com) 
Search Strategy # Query Results 
#1 'breast'/exp 83,921 
#2 breast* 523,538 
#3 mammary 107,156 
#4 #1 OR #2 OR #3 574,130 
#5 'neoplasm'/exp 3,360,234 
#6 neoplasm* 3,372,019 
#7 cancer* 2,817,176 
#8 malign* 2,042,448 
#9 tumor* 3,426,236 
#10 tumour* 257,374 
#11 carcinom* 941,106 
#12 adenocarcinom* 170,161 
#13 metastas* 457,613 
#14 oncolog* 1,525,312 
#15 #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 4,391,625 
#16 #4 AND #15 424,264 
#17 'breast tumor'/exp 343,775 
#18 #16 OR #17 424,264 
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#19 'tumor suppressor gene'/exp 44,388 
#20 'genetic predisposition'/exp 75,976 
#21 'genetic counseling'/exp 20,646 
#22 'genetic marker'/exp 54,975 
#23 'genetic polymorphism'/exp 284,048 
#24 'single strand conformation polymorphism'/exp 10,637 
#25 #19 OR #20 OR #21 OR #22 OR #23 OR #24 434,409 
#26 'genetic screening'/exp 43,332 
#27 'heterozygote detection'/exp 5,825 
#28 genet* NEAR/3 (test* OR screened OR screening OR detect* OR assess* OR profil* OR 
counseling OR counselling) 
175,330 
#29 #26 OR #27 OR #28 175,330 
#30 #18 AND #29 10,569 
#31 (hereditary OR famil* OR genetic* OR inherited) NEAR/3 (cancer* OR tumor* OR tumour* 
OR neoplasm* OR carcinom* OR adenocarcinom*) 
230,723 
#32 screening 643,614 
#33 screened 119,165 
#34 testing 551,278 
#35 test 2,051,766 
#36 tests 1,135,998 
#37 profile 334,086 
#38 profiling 98,050 
#39 detect* 1,953,108 
#40 assess* 2,761,457 
#41 #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40 7,144,115 
#42 gene OR genes 2,931,723 
#43 genetic OR genetics 4,358,988 
#44 mutation OR mutations 840,487 
#45 allele OR alleles 210,782 
#46 brca* OR '17q12-21' OR '17q12-q21' OR '17q12' OR '17q21' OR '13q12-13' OR '13q12-q13' 
OR '13q12-3' 
22,792 
#47 tp53 OR 17p13.1 8,066 
#48 stk2 OR 19p13.3 356 
#49 stkii 3 
#50 chek2 OR 22q12.1 532 
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#51 11q22.3 212 
#53 atm NEAR/2 (gene OR locus OR loci) 1,081 
#54 cdh1 OR 16q22.1 1,983 
#55 pten OR 10q23.3 11,402 
#56 palb2 OR 16p12.1 357 
#57 bardi OR 2q34 OR 2q35 OR '2q34-q35' OR '2q34-35' OR '2q34-5' 935 
#58 brip1 OR 17q22 OR 17q23 OR 17q24 OR '17q22-q24' OR '17q22-24' OR '17q22-4' 924 
#59 mre11a OR 11q21 267 
#60 nbn OR 8q21 596 
#61 rad50 OR 5q31 2,416 
#62 rad51c OR 17q25.1 266 
#63 xrcc2 OR 7q36.1 336 
#64 rad51d OR 17q11 699 
#65 abraxas OR 4q21.23 140 
#66 her2 19,433 
#67 #42 OR #43 OR #44 OR #45 OR #46 OR #47 OR #48 OR #49 OR #50 OR #51 OR #53 OR 
#54 OR #55 OR #56 OR #57 OR #58 OR #59 OR #60 OR #61 OR #62 OR #63 OR #64 OR 
#65 OR #66 
4,599,489 
#68 (screening OR screened OR testing OR test OR tests OR profile OR profiling OR detect* OR 
assess* OR sequencing) NEAR/3 (gene OR genes OR genetic OR genetics OR mutation OR 
mutations OR allele OR alleles OR brca* OR tp53 OR stk2 OR stkii OR chek2 OR her2 OR 
abraxas OR 4q21.23 OR rad51d OR 17q11 OR xrcc2 OR 7q36.1 OR rad51c OR 17q25.1 OR 
rad50 OR 5q31 OR nbn OR 8q21 OR mre11a OR 11q21 OR brip1 OR 17q22 OR 17q23 OR 
17q24 OR '17q22-q24' OR '17q22-24' OR '17q22-4' OR bardi OR 2q34 OR 2q35 OR '2q34-
q35' OR '2q34-35' OR '2q34-5' OR palb2 OR 16p12.1 OR pten OR 10q23.3 OR cdh1 OR 
16q22.1 OR 11q22.3 OR check2 OR 22q12.1 OR stkii OR stk2 OR 19p13.3 OR 17p13.1 OR 
'17q12-21' OR '17q12-q21' OR '17q12' OR 17q21 OR '13q12-13' OR '13q12-q13' OR '13q12-
3' OR 13q13) 
240,809 
#69 #18 AND #68 15,243 
#70 'familial cancer'/exp 9,475 
#71 #4 AND #70 3,377 
#72 #41 AND #71 2,205 
#73 #25 AND #41 187,429 
#74 'mass screening'/exp 150,737 
#75 'microarray analysis'/exp 36,159 
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#76 'health survey'/exp 150,475 
#77 #74 OR #75 OR #76 332,748 
#78 #25 AND #77 21,677 
#79 #73 OR #78 189,146 
#80 #18 AND #79 11,007 
#81 #4 AND #31 AND #41 18,845 
#82 #30 OR #69 OR #72 OR #80 OR #81 30,560 
#83 'meta-analysis'/exp OR 'meta-analysis' OR 'systematic review'/exp OR 'systematic review' 159,496 
#84 #82 AND #83 762 
#85 #84 AND [embase]/lim 725 
#86 #84 AND [medline]/lim 556 
#87 #84 NOT #86 366 
Note  
Appendix 2.1.3. Cochrane 
Date 2014-02-07 
Database  
(name + access ; e.g.: 
Medline OVID) 
Cochrane Database 
Search Strategy # Search expression Results 
#1 MeSH descriptor: [Breast] explode all trees 591 
#2 breast*:ti,ab,kw  20645 
#3 mammary:ti,ab,kw  773 
#4 #1 or #2 or #3  21056 
#5 MeSH descriptor: [Neoplasms] explode all trees 49379 
#6 neoplasm*:ti,ab,kw  44175 
#7 cancer*:ti,ab,kw  55325 
#8 tumor*:ti,ab,kw  18655 
#9 tumour*:ti,ab,kw  4386 
#10 carcinom*:ti,ab,kw  18053 
#11 adenocarcin*:ti,ab,kw  3362 
#12 malign*:ti,ab,kw  7257 
#13 metasta*:ti,ab,kw  12967 
#14 oncolog*:ti,ab,kw  9630 
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#15 #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14  86028 
#16 #5 or #15  91175 
#17 #4 and #16  16392 
#18 MeSH descriptor: [Breast Neoplasms] explode all trees 8274 
#19 #17 or #18  16392 
#20 MeSH descriptor: [Genetic Predisposition to Disease] explode all trees 1326 
#21 MeSH descriptor: [Genetics] explode all trees 577 
#22 MeSH descriptor: [Genetic Markers] explode all trees 213 
#23 MeSH descriptor: [Polymorphism, Genetic] explode all trees 2718 
#24 Polymorphism, single stranded conformational  52 
#25 #20 or #21 or #22 or #23 or #24  3692 
#26 screening:ti,ab,kw  18362 
#27 screened:ti,ab,kw  18522 
#28 testing:ti,ab,kw  143378 
#29 tests:ti,ab,kw  143679 
#30 tested:ti,ab,kw  143453 
#31 test:ti,ab,kw  143679 
#32 profil*:ti,ab,kw  25734 
#33 #26 or #27 or #28 or #29 or #30 or #31 or #32  174355 
#34 Any MeSH descriptor with qualifier(s): [Diagnosis - DI] 36637 
#35 diagnosis:ti,ab,kw  29655 
#36 detection:ti,ab,kw  11081 
#37 #34 or #35 or #36  67110 
#38 #37 and #25  407 
#39 MeSH descriptor: [Genetic Testing] explode all trees 464 
#40 MeSH descriptor: [Genetic Counseling] explode all trees 137 
#41 MeSH descriptor: [DNA Mutational Analysis] explode all trees 224 
#42 MeSH descriptor: [Heterozygote Detection] explode all trees 65 
#43 MeSH descriptor: [Genetic Techniques] explode all trees 4393 
#44 MeSH descriptor: [Microarray Analysis] explode all trees 237 
#45 #39 or #40 or #41 or #42 or #43 or #44  4479 
#46 (genet* near/3 (test* or screened or screening or detect* or assess* or profil* or counseling 
or counselling)):ti,ab,kw  
1123 
#47 ((proteom* or genom* or gene or genes or sequence or sequences) near/3 (screening or 
profil* or sequencing or screening or screened)):ti,ab,kw  
9031 
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#48 expression near/3 profil*:ti,ab,kw  457 
#49 #46 or #47 or #48  10052 
#50 #38 or #45 or #49  13187 
#51 MeSH descriptor: [Mass Screening] explode all trees 4732 
#52 MeSH descriptor: [Population Surveillance] explode all trees 501 
#53 #51 or #52  5164 
#54 #33 or #53  174803 
#55 #25 and #54  1264 
#56 #50 or #55  13662 
#57 #19 and #56  656 
#58 MeSH descriptor: [Breast Neoplasms] explode all trees and with qualifier(s): [Genetics - GE] 430 
#59 MeSH descriptor: [Genes, BRCA1] explode all trees 72 
#60 MeSH descriptor: [Genes, BRCA2] explode all trees 52 
#61 #58 or #59 or #60  448 
#62 MeSH descriptor: [Breast Neoplasms] explode all trees and with qualifier(s): [Diagnosis - DI] 603 
#63 #50 or #54 or #62  182317 
#64 #61 and #63  318 
#65 MeSH descriptor: [Neoplasms] explode all trees and with qualifier(s): [Genetics - GE] 1770 
#66 MeSH descriptor: [Neoplastic Syndromes, Hereditary] explode all trees 269 
#67 ((hereditary or famil* or genetic* or inherited) near/3 (cancer or cancers or tumor* or tumour* 
or neoplasm* or carcinom* or adenocarcinom*)):ti,ab,kw  
869 
#68 #65 or #66 or #67  2427 
#69 #68 and #4  566 
#70 #54 or #50  182082 
#71 #69 and #70  375 
#72 #57 or #64 or #71  729 
#73 gene:ti,ab,kw or genes:ti,ab,kw  7172 
#74 genetic:ti,ab,kw  6489 
#75 genetics:ti,ab,kw  752 
#76 mutations:ti,ab,kw or mutation:ti,ab,kw  2341 
#77 allele or alleles  1890 
#78 BRCA*:ti,ab,kw  175 
#79 TP53:ti,ab,kw  55 
#80 STK2:ti,ab,kw  0 
#81 STKII:ti,ab,kw  0 
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#82 CHEK2:ti,ab,kw  7 
#83 HER2:ti,ab,kw  541 
#84 ('17q12-21' or '17q12-q21' or '17q12' or '17q21' or '13q12-13' or '13q12-q13' or '13q12-
3'):ti,ab,kw  
2 
#85 "17p13.1":ti,ab,kw  3 
#86 "19p13.3":ti,ab,kw  0 
#87 "22q12.1":ti,ab,kw  0 
#88 "11q22.3":ti,ab,kw  1 
#89 (atm near/2 (gene or locus or loci)):ti,ab,kw  5 
#90 (cdh1 or "16q22.1"):ti,ab,kw  4 
#91 (palb2 or "16p12.1"):ti,ab,kw  0 
#92 (pten or "10q23.3"):ti,ab,kw  36 
#93 (bardi or "2q34" or "2q35" or "2q34-q35" or "2q34-35" or "2q34-5"):ti,ab,kw  2 
#94 (mre11a or "11q21"):ti,ab,kw  0 
#95 (brip1 or "17q22" or "17q23" or "17q24" or "17q22-q24" or "17q22-24" or "17q22-4"):ti,ab,kw 0 
#96 (nbn or "8q21"):ti,ab,kw  5 
#97 (rad50 or "5q31"):ti,ab,kw  2 
#98 (rad51c or "17q25.1"):ti,ab,kw  0 
#99 (xrcc2 or "7q36.1"):ti,ab,kw  2 
#100 (rad51d or "17q11"):ti,ab,kw  0 
#101 (abraxas or "4q21.23"):ti,ab,kw  0 
#102 #73 or #74 or #75 or #76 or #77 or #78 or #79 or #80 or #81 or #82 or #83 or #84 or #85 or 
#86 or #87 or #88 or #89 or #90 or #91 or #92 or #93 or #94 or #95 or #96 or #97 or #98 or 
#99 or #100 or #101  
12943 
#103 assess*:ti,ab,kw  172767 
#104 detect*:ti,ab,kw  35782 
#105 sequencing:ti,ab,kw  8687 
#106 #33 or #103 or #104 or #105  308045 
#107 (screening or screened or testing or tests or test or tested or profil* or assess* or detect* or 
sequencing) near/3 (gene or genes or genetic or genetics or mutation or mutations or allele 
or alleles or BRCA* or TP53 or STK2 or STKII or CHEK2 or HER2 or ('17q12-21' or '17q12-
q21' or '17q12' or '17q21' or '13q12-13' or '13q12-q13' or '13q12-3') or "17p13.1" or "19p13.3" 
or "22q12.1" or "11q22.3" or (atm adj2 (gene or locus or loci)) or (cdh1 or "16q22.1") or (pten 
or "10q23.3") or (palb2 or "16p12.1") or (bardi or "2q34" or "2q35" or "2q34-q35" or "2q34-35" 
or "2q34-5") or (brip1 or "17q22" or "17q23" or "17q24" or "17q22-q24" or "17q22-24" or 
2168 
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"17q22-4") or (mre11a or "11q21") or (nbn or "8q21") or (rad50 or "5q31") or (rad51c or 
"17q25.1") or (xrcc2 or "7q36.1") or (rad51d or "17q11") or (abraxas or "4q21.23")):ti,ab,kw  
#108 #107 and #19  288 
#109 EndoPredict  1 
#110 PAM50  5 
#111 "Genomic Grade Index"  1 
#112 MammaPrint  12 
#113 oncotypedx or "oncotype dx"  20 
#114 "Breast Cancer Index"  2 
#115 #109 or #110 or #111 or #112 or #113 or #114  35 
#116 (screening or screened or testing or tests or test or tested or profil* or assess* or detect* or 
sequencing) near/3 ((tumor* or tumour*) or cancer* or oncolog* or metastas* or carcinom* or 
malign* or adenocarinom* or neoplas*)  
7492 
#117 #116 and #4  1720 
#118 #25 or #45 or #68 or #102  15513 
#119 #117 and #118  246 
#120 #119 or #115 or #108 or #72  817 
Note 817 results for Cochrane library split as: 
All Results (817) 
Cochrane Reviews (9) 
DARE (32)  
CENTRAL (649)  
Methods Studies -CMR (9)  
Technology Assessments – HTAD (52)  
Economic Evaluations NHSEED (66)  
Cochrane Groups – ABOUT (0) 
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Appendix 2.2. Cowden 
Appendix 2.2.1. Medline @ Ovid 
Date 2014-03-13 
Database  Medline (OVID) 
Search Strategy 
 
# Query Results 
1 cowden's syndrome.mp.  84 
2 Hamartoma Syndrome, Multiple/  753 
3 bannayan-ruvalcaba-riley.mp.  8 
4 cowden's disease.mp.  191 
5 myhre riley smith syndrome.mp.  0 
6 multiple hamartoma syndromes.mp.  3 
7 cerebellum dysplastic gangliocytoma?.mp.  0 
8 ruvalcaba myhre smith syndrome.mp.  14 
9 (macrocephaly pseudopapilledema and multiple hemangiomas).mp. 0 
10 dysplastic gangliocytoma of cerebellum.mp.  9 
11 cerebellum dysplastic gangliocytoma.mp.  0 
12 lhermitte duclos disease.mp.  216 
13 cowden syndrome.mp.  364 
14 hamartoma syndrome multiple.mp.  753 
15 dysplastic gangliocytoma of the cerebellum.mp.  55 
16 riley smith syndrome.mp.  4 
17 cowdens disease.mp.  191 
18 myhre-riley-smith syndrome.mp.  0 
19 myhre-riley-smith.mp.  0 
20 pten hamartoma tumor.mp.  73 
21 bannayan zonana syndrome.mp.  42 
22 hamartoma syndromes multiple.mp.  0 
23 hamartoma syndromes.mp.  44 
24 multiple hamartoma syndrome.mp.  111 
25 bannayan riley ruvalcaba syndrome.mp.  100 
26 bannayan-riley-ruvalcaba syndrome.mp.  100 
27 cowden disease.mp.  193 
28 ruvalcaba-myhre syndrome.mp.  2 
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29 bannayan-zonana syndrome.mp.  42 
30 (macrocephaly multiple lipomas and hemangiomata).mp.  1 
31 (macrocephaly pseudopapilledema and multiple hemangiomata).mp.  0 
32 lhermitte-duclos disease.mp.  216 
33 ruvalcaba-myhre-smith syndrome.mp.  14 
34 riley-smith syndrome.mp.  4 
35 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 
19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34  
1294 
36 (pten adj3 hamartoma).mp.  98 
37 cowden.ti,ab.  643 
38 (germline adj5 hamartom*).mp.  15 
39 (hamartoma? adj3 (syndrome? or pten or multiple)).tw.  696 
40 36 or 37 or 38 or 39  1176 
41 35 or 40  1714 
42 exp Genetic Predisposition to Disease/  88227 
43 exp Genetics/  171946 
44 exp Genetic markers/  44777 
45 exp Polymorphism, genetic/  193770 
46 exp Polymorphism, single stranded conformational/  10356 
47 42 or 43 or 44 or 45 or 46  424611 
48 (screening or screened or testing or test? or tested or profil*).tw,kw,kf.  2668335 
49 di.xs. or diagnosis.tw,kw,kf. or detection.tw,kw,kf.  5054368 
50 47 and 49  85156 
51 exp Genetic testing/  25803 
52 exp genetic counseling/  11659 
53 exp DNA mutational analysis/  46011 
54 exp Heterozygote Detection/  8036 
55 exp Genetic Techniques/  1483281 
56 exp Microarray Analysis/  72581 
57 51 or 52 or 53 or 54 or 55 or 56  1495091 
58 (genet* adj3 (test* or screened or screening or detect* or assess* or profil* or 
counsel?ing)).tw,kw.  
43996 
59 ((proteom* or genom* or gene? or sequence?) adj3 (screening or profil* or sequencing or 
screening or screened)).tw,kw.  
69890 
60 (expression adj3 profil*).tw,kw.  47657 
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61 58 or 59 or 60  132885 
62 50 or 57 or 61  1582390 
63 exp Mass Screening/  98780 
64 exp population surveillance/  49240 
65 63 or 64  145808 
66 48 or 65  2734065 
67 47 and 66  94841 
68 62 or 67  1609544 
69 41 and 68  458 
70 Hamartoma Syndrome, Multiple/ge  397 
71 70 and (48 or 49 or 57 or 61 or 65)  328 
72 69 or 71  585 
73 Hamartoma Syndrome, Multiple/di  234 
74 (73 or 66 or 62) and 70  267 
75 69 or 71 or 74  585 
76 limit 75 to systematic reviews  6 
Note    
Appendix 2.2.2. Medline @ Pubmed 
Date 2014-03-06 
Database  Medline (Pubmed) 
Search Strategy 
(attention, for PubMed, 
check « Details ») 
# Query Results 
1 ("hamartoma syndrome, multiple"[MeSH Terms] OR ("hamartoma"[All Fields] AND 
"syndrome"[All Fields] AND "multiple"[All Fields]) OR "multiple hamartoma syndrome"[All 
Fields] OR ("hamartoma"[All Fields] AND "syndromes"[All Fields] AND "multiple"[All Fields])) 
OR "Multiple Hamartoma Syndromes"[All Fields] OR "Multiple Hamartoma Syndrome"[All 
Fields] OR "Cowden's Disease"[All Fields] OR ("hamartoma syndrome, multiple"[MeSH 
Terms] OR ("hamartoma"[All Fields] AND "syndrome"[All Fields] AND "multiple"[All Fields]) 
OR "multiple hamartoma syndrome"[All Fields] OR ("cowdens"[All Fields] AND "disease"[All 
Fields])) OR "Cowden's Syndrome"[All Fields] OR "Cowdens Syndrome"[All Fields] OR 
"Cowden Disease"[All Fields] OR "Cowden Syndrome"[All Fields] OR "Lhermitte-Duclos 
Disease"[All Fields] OR "Lhermitte Duclos Disease"[All Fields] OR "Dysplastic Gangliocytoma 
of Cerebellum"[All Fields] OR ("hamartoma syndrome, multiple"[MeSH Terms] OR 
("hamartoma"[All Fields] AND "syndrome"[All Fields] AND "multiple"[All Fields]) OR "multiple 
hamartoma syndrome"[All Fields] OR ("cerebellum"[All Fields] AND "dysplastic"[All Fields] 
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AND "gangliocytoma"[All Fields])) OR ("hamartoma syndrome, multiple"[MeSH Terms] OR 
("hamartoma"[All Fields] AND "syndrome"[All Fields] AND "multiple"[All Fields]) OR "multiple 
hamartoma syndrome"[All Fields] OR ("cerebellum"[All Fields] AND "dysplastic"[All Fields] 
AND "gangliocytomas"[All Fields])) OR "Dysplastic Gangliocytoma of the Cerebellum"[All 
Fields] OR "PTEN Hamartoma Tumor Syndrome"[All Fields] OR "Bannayan-Riley-Ruvalcaba 
Syndrome"[All Fields] OR "Bannayan Riley Ruvalcaba Syndrome"[All Fields] OR 
"Macrocephaly, Multiple Lipomas, and Hemangiomata"[All Fields] OR ("hamartoma 
syndrome, multiple"[MeSH Terms] OR ("hamartoma"[All Fields] AND "syndrome"[All Fields] 
AND "multiple"[All Fields]) OR "multiple hamartoma syndrome"[All Fields] OR 
("macrocephaly"[All Fields] AND "pseudopapilledema"[All Fields] AND "multiple"[All Fields] 
AND "hemangiomas"[All Fields])) OR "Ruvalcaba-Myhre Syndrome"[All Fields] OR 
("hamartoma syndrome, multiple"[MeSH Terms] OR ("hamartoma"[All Fields] AND 
"syndrome"[All Fields] AND "multiple"[All Fields]) OR "multiple hamartoma syndrome"[All 
Fields] OR ("myhre"[All Fields] AND "riley"[All Fields] AND "smith"[All Fields] AND 
"syndrome"[All Fields])) OR ("hamartoma syndrome, multiple"[MeSH Terms] OR 
("hamartoma"[All Fields] AND "syndrome"[All Fields] AND "multiple"[All Fields]) OR "multiple 
hamartoma syndrome"[All Fields] OR ("myhre"[All Fields] AND "riley"[All Fields] AND 
"smith"[All Fields] AND "syndrome"[All Fields])) OR "Riley-Smith Syndrome"[All Fields] OR 
"Riley Smith Syndrome"[All Fields] OR "Ruvalcaba-Myhre-Smith Syndrome"[All Fields] OR 
"Ruvalcaba Myhre Smith Syndrome"[All Fields] OR "Bannayan-Ruvalcaba-Riley 
Syndrome"[All Fields] OR "Bannayan-Zonana Syndrome"[All Fields] OR "Bannayan Zonana 
Syndrome"[All Fields] OR ("hamartoma syndrome, multiple"[MeSH Terms] OR 
("hamartoma"[All Fields] AND "syndrome"[All Fields] AND "multiple"[All Fields]) OR "multiple 
hamartoma syndrome"[All Fields] OR ("macrocephaly"[All Fields] AND 
"pseudopapilledema"[All Fields] AND "multiple"[All Fields] AND "hemangiomata"[All Fields])) 
 
2 Limit 1 to systematic reviews 8 
Note  Few reviews, no need to look for genetic testing.  
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Appendix 2.2.3. Embase @ Embase.com 
Date 2014-03-12 
Database  Embase (Embase.com) 
Search Strategy 
(attention, for PubMed, 
check « Details ») 
# Query Results 
#1 multiple NEAR/4 hamartom* 903 
#2 hamartom* NEAR/4 syndrome 1,174 
#3 #1 AND #2 310 
#4 'bannayan ruvalcaba riley' 14 
#5 cowden NEAR/2 disease 531 
#6 cowdens NEAR/2 disease 1 
#7 myhre AND riley AND smith AND syndrome 6 
#8 cowden NEAR/2 syndrome 1,309 
#9 cowdens NEAR/2 syndrome 3 
#10 multiple AND hamartoma AND syndromes 154 
#11 cerebellum AND dysplastic AND gangliocytom* 128 
#12 ruvalcaba AND myhre AND smith AND syndrome 24 
#13 macrocephaly AND pseudopapilledema AND multiple AND hemangiomas 0 
#14 dysplastic AND gangliocytoma AND of AND cerebellum 124 
#15 cerebellum AND dysplastic AND gangliocytoma 124 
#16 lhermitte AND duclos AND disease 387 
#17 dysplastic AND gangliocytoma AND of AND the AND cerebellum 119 
#18 riley AND smith AND syndrome 53 
#19 'myhre riley smith' AND syndrome 0 
#20 'myhre riley smith' 0 
#21 pten AND hamartoma AND tumor 299 
#22 bannayan AND zonana AND syndrome 67 
#23 hamartoma AND syndromes AND multiple 154 
#24 hamartoma AND syndromes 376 
#25 multiple AND hamartoma AND syndrome 809 
#26 bannayan AND riley AND ruvalcaba AND syndrome 202 
#27 'bannayan riley ruvalcaba' AND syndrome 186 
#28 'ruvalcaba myhre' AND syndrome 32 
#29 'bannayan zonana' AND syndrome 66 
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#30 macrocephaly AND multiple AND lipomas AND hemangiomata 1 
#31 macrocephaly AND pseudopapilledema AND multiple AND hemangiomata 0 
#32 'lhermitte duclos' AND disease 385 
#33 'ruvalcaba myhre smith' AND syndrome 18 
#34 'riley smith' AND syndrome 9 
#35 #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR 
#15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR 
#26 OR #27 OR #28 OR #29 OR #30 OR #31 OR #32 OR #33 OR #34 
2,543 
#36 'meta-analysis'/exp OR 'meta-analysis' OR 'systematic review'/exp OR 'systematic review' 163,032 
#37 #35 AND #36 18 
Note    
Appendix 2.2.4. Cochrane Database of Systematic Reviews 
Date 2014-03-17 
Database  Cochrane 
Search Strategy 
(attention, for PubMed, 
check « Details ») 
# Query Results 
#1 cowden's syndrome  0 
#2 cowden:ti  1 
#3 MeSH descriptor: [Hamartoma Syndrome, Multiple] explode all trees 1 
#4 bannayan-ruvalcaba-riley:ti,ab,kw  0 
#5 "cowden's disease":ti,ab,kw  0 
#6 "myhre riley smith syndrome":ti,ab,kw  0 
#7 "multiple hamartoma syndromes":ti,ab,kw  0 
#8 "cerebellum dysplastic gangliocytoma":ti,ab,kw  0 
#9 "cerebellum dysplastic gangliocytomas":ti,ab,kw  0 
#10 "ruvalcaba myhre smith syndrome":ti,ab,kw  0 
#11 "macrocephaly pseudopapilledema and multiple hemangiomas":ti,ab,kw  0 
#12 "dysplastic gangliocytoma of cerebellum":ti,ab,kw  0 
#13 "cerebellum dysplastic gangliocytoma":ti,ab,kw  0 
#14 "lhermitte duclos disease":ti,ab,kw  0 
#15 "cowden syndrome":ti,ab,kw  1 
#16 "hamartoma syndrome multiple":ti,ab,kw  1 
#17 "dysplastic gangliocytoma of the cerebellum":ti,ab,kw  0 
#18 "riley smith syndrome":ti,ab,kw  0 
#19 "cowdens disease":ti,ab,kw  0 
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#20 "myhre-riley-smith syndrome":ti,ab,kw  0 
#21 "myhre-riley-smith":ti,ab,kw  0 
#22 "pten hamartoma tumor":ti,ab,kw  1 
#23 "bannayan zonana syndrome":ti,ab,kw  0 
#24 "hamartoma syndromes multiple":ti,ab,kw  0 
#25 "hamartoma syndromes":ti,ab,kw  0 
#26 "multiple hamartoma syndrome":ti,ab,kw  0 
#27 "bannayan riley ruvalcaba syndrome":ti,ab,kw  0 
#28 "bannayan-riley-ruvalcaba syndrome":ti,ab,kw  0 
#29 "cowden disease":ti,ab,kw  0 
#30 "ruvalcaba-myhre syndrome":ti,ab,kw  0 
#31 "bannayan-zonana syndrome":ti,ab,kw  0 
#32 "macrocephaly multiple lipomas and hemangiomata":ti,ab,kw  0 
#33 "macrocephaly pseudopapilledema and multiple hemangiomata":ti,ab,kw  0 
#34 "lhermitte-duclos disease":ti,ab,kw  0 
#35 "ruvalcaba-myhre-smith syndrome":ti,ab,kw  0 
#36 "riley-smith syndrome":ti,ab,kw  0 
#37 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 
or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28 
or #29 or #30 or #31 or #32 or #33 or #34 or #35 or #36  
2 
#38 (pten near/3 hamartoma):ti,ab,kw  1 
#39 cowden:ti,ab,kw  1 
#40 (germline near/5 hamartom*):ti,ab,kw  0 
#41 (hamartom* near/3 (syndrom* or pten or multiple)):ti,ab  1 
#42 #38 or #39 or #40 or #41  2 
#43 #37 or #42  2 
Note  2 results: 1 Trial and 1 HTA  
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Appendix 2.3. Li-Fraumeni syndrome 
Appendix 2.3.1. Medline @ Ovid 
Date 2014-03-13 
Database  Medline (OVID) 
Search Strategy 
 
# Query Results 
1 cowden's syndrome.mp.  84 
2 Hamartoma Syndrome, Multiple/  753 
3 bannayan-ruvalcaba-riley.mp.  8 
4 cowden's disease.mp.  191 
5 myhre riley smith syndrome.mp.  0 
6 multiple hamartoma syndromes.mp.  3 
7 cerebellum dysplastic gangliocytoma?.mp.  0 
8 ruvalcaba myhre smith syndrome.mp.  14 
9 (macrocephaly pseudopapilledema and multiple hemangiomas).mp. 0 
10 dysplastic gangliocytoma of cerebellum.mp.  9 
11 cerebellum dysplastic gangliocytoma.mp.  0 
12 lhermitte duclos disease.mp.  216 
13 cowden syndrome.mp.  364 
14 hamartoma syndrome multiple.mp.  753 
15 dysplastic gangliocytoma of the cerebellum.mp.  55 
16 riley smith syndrome.mp.  4 
17 cowdens disease.mp.  191 
18 myhre-riley-smith syndrome.mp.  0 
19 myhre-riley-smith.mp.  0 
20 pten hamartoma tumor.mp.  73 
21 bannayan zonana syndrome.mp.  42 
22 hamartoma syndromes multiple.mp.  0 
23 hamartoma syndromes.mp.  44 
24 multiple hamartoma syndrome.mp.  111 
25 bannayan riley ruvalcaba syndrome.mp.  100 
26 bannayan-riley-ruvalcaba syndrome.mp.  100 
27 cowden disease.mp.  193 
28 ruvalcaba-myhre syndrome.mp.  2 
29 bannayan-zonana syndrome.mp.  42 
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30 (macrocephaly multiple lipomas and hemangiomata).mp.  1 
31 (macrocephaly pseudopapilledema and multiple hemangiomata).mp.  0 
32 lhermitte-duclos disease.mp.  216 
33 ruvalcaba-myhre-smith syndrome.mp.  14 
34 riley-smith syndrome.mp.  4 
35 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 
19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34  
1294 
36 (pten adj3 hamartoma).mp.  98 
37 cowden.ti,ab.  643 
38 (germline adj5 hamartom*).mp.  15 
39 (hamartoma? adj3 (syndrome? or pten or multiple)).tw.  696 
40 36 or 37 or 38 or 39  1176 
41 35 or 40  1714 
42 exp Genetic Predisposition to Disease/  88227 
43 exp Genetics/  171946 
44 exp Genetic markers/  44777 
45 exp Polymorphism, genetic/  193770 
46 exp Polymorphism, single stranded conformational/  10356 
47 42 or 43 or 44 or 45 or 46  424611 
48 (screening or screened or testing or test? or tested or profil*).tw,kw,kf.  2668335 
49 di.xs. or diagnosis.tw,kw,kf. or detection.tw,kw,kf.  5054368 
50 47 and 49  85156 
51 exp Genetic testing/  25803 
52 exp genetic counseling/  11659 
53 exp DNA mutational analysis/  46011 
54 exp Heterozygote Detection/  8036 
55 exp Genetic Techniques/  1483281 
56 exp Microarray Analysis/  72581 
57 51 or 52 or 53 or 54 or 55 or 56  1495091 
58 (genet* adj3 (test* or screened or screening or detect* or assess* or profil* or 
counsel?ing)).tw,kw.  
43996 
59 ((proteom* or genom* or gene? or sequence?) adj3 (screening or profil* or sequencing or 
screening or screened)).tw,kw.  
69890 
60 (expression adj3 profil*).tw,kw.  47657 
61 58 or 59 or 60  132885 
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62 50 or 57 or 61  1582390 
63 exp Mass Screening/  98780 
64 exp population surveillance/  49240 
65 63 or 64  145808 
66 48 or 65  2734065 
67 47 and 66  94841 
68 62 or 67  1609544 
69 41 and 68  458 
70 Hamartoma Syndrome, Multiple/ge  397 
71 70 and (48 or 49 or 57 or 61 or 65)  328 
72 69 or 71  585 
73 Hamartoma Syndrome, Multiple/di  234 
74 (73 or 66 or 62) and 70  267 
75 69 or 71 or 74  585 
76 limit 75 to systematic reviews  6 
Note    
Appendix 2.3.2. Medline @ Pubmed 
Date 2014-03-06 
Database  Medline (Pubmed) 
Search Strategy 
(attention, for PubMed, 
check « Details ») 
# Query Results 
1 ("hamartoma syndrome, multiple"[MeSH Terms] OR ("hamartoma"[All Fields] AND 
"syndrome"[All Fields] AND "multiple"[All Fields]) OR "multiple hamartoma syndrome"[All 
Fields] OR ("hamartoma"[All Fields] AND "syndromes"[All Fields] AND "multiple"[All Fields])) 
OR "Multiple Hamartoma Syndromes"[All Fields] OR "Multiple Hamartoma Syndrome"[All 
Fields] OR "Cowden's Disease"[All Fields] OR ("hamartoma syndrome, multiple"[MeSH 
Terms] OR ("hamartoma"[All Fields] AND "syndrome"[All Fields] AND "multiple"[All Fields]) 
OR "multiple hamartoma syndrome"[All Fields] OR ("cowdens"[All Fields] AND "disease"[All 
Fields])) OR "Cowden's Syndrome"[All Fields] OR "Cowdens Syndrome"[All Fields] OR 
"Cowden Disease"[All Fields] OR "Cowden Syndrome"[All Fields] OR "Lhermitte-Duclos 
Disease"[All Fields] OR "Lhermitte Duclos Disease"[All Fields] OR "Dysplastic Gangliocytoma 
of Cerebellum"[All Fields] OR ("hamartoma syndrome, multiple"[MeSH Terms] OR 
("hamartoma"[All Fields] AND "syndrome"[All Fields] AND "multiple"[All Fields]) OR "multiple 
hamartoma syndrome"[All Fields] OR ("cerebellum"[All Fields] AND "dysplastic"[All Fields] 
AND "gangliocytoma"[All Fields])) OR ("hamartoma syndrome, multiple"[MeSH Terms] OR 
("hamartoma"[All Fields] AND "syndrome"[All Fields] AND "multiple"[All Fields]) OR "multiple 
1848 
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hamartoma syndrome"[All Fields] OR ("cerebellum"[All Fields] AND "dysplastic"[All Fields] 
AND "gangliocytomas"[All Fields])) OR "Dysplastic Gangliocytoma of the Cerebellum"[All 
Fields] OR "PTEN Hamartoma Tumor Syndrome"[All Fields] OR "Bannayan-Riley-Ruvalcaba 
Syndrome"[All Fields] OR "Bannayan Riley Ruvalcaba Syndrome"[All Fields] OR 
"Macrocephaly, Multiple Lipomas, and Hemangiomata"[All Fields] OR ("hamartoma 
syndrome, multiple"[MeSH Terms] OR ("hamartoma"[All Fields] AND "syndrome"[All Fields] 
AND "multiple"[All Fields]) OR "multiple hamartoma syndrome"[All Fields] OR 
("macrocephaly"[All Fields] AND "pseudopapilledema"[All Fields] AND "multiple"[All Fields] 
AND "hemangiomas"[All Fields])) OR "Ruvalcaba-Myhre Syndrome"[All Fields] OR 
("hamartoma syndrome, multiple"[MeSH Terms] OR ("hamartoma"[All Fields] AND 
"syndrome"[All Fields] AND "multiple"[All Fields]) OR "multiple hamartoma syndrome"[All 
Fields] OR ("myhre"[All Fields] AND "riley"[All Fields] AND "smith"[All Fields] AND 
"syndrome"[All Fields])) OR ("hamartoma syndrome, multiple"[MeSH Terms] OR 
("hamartoma"[All Fields] AND "syndrome"[All Fields] AND "multiple"[All Fields]) OR "multiple 
hamartoma syndrome"[All Fields] OR ("myhre"[All Fields] AND "riley"[All Fields] AND 
"smith"[All Fields] AND "syndrome"[All Fields])) OR "Riley-Smith Syndrome"[All Fields] OR 
"Riley Smith Syndrome"[All Fields] OR "Ruvalcaba-Myhre-Smith Syndrome"[All Fields] OR 
"Ruvalcaba Myhre Smith Syndrome"[All Fields] OR "Bannayan-Ruvalcaba-Riley 
Syndrome"[All Fields] OR "Bannayan-Zonana Syndrome"[All Fields] OR "Bannayan Zonana 
Syndrome"[All Fields] OR ("hamartoma syndrome, multiple"[MeSH Terms] OR 
("hamartoma"[All Fields] AND "syndrome"[All Fields] AND "multiple"[All Fields]) OR "multiple 
hamartoma syndrome"[All Fields] OR ("macrocephaly"[All Fields] AND 
"pseudopapilledema"[All Fields] AND "multiple"[All Fields] AND "hemangiomata"[All Fields])) 
2 Limit 1 to systematic reviews 8 
Note  Few reviews, no need to look for genetic testing.  
Appendix 2.3.3. Embase @ Embase.com 
Date 2014-03-12 
Database  Embase (Embase.com) 
Search Strategy 
(attention, for PubMed, 
check « Details ») 
# Query Results 
#1 multiple NEAR/4 hamartom* 903 
#2 hamartom* NEAR/4 syndrome 1,174 
#3 #1 AND #2 310 
#4 'bannayan ruvalcaba riley' 14 
#5 cowden NEAR/2 disease 531 
#6 cowdens NEAR/2 disease 1 
#7 myhre AND riley AND smith AND syndrome 6 
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#8 cowden NEAR/2 syndrome 1,309 
#9 cowdens NEAR/2 syndrome 3 
#10 multiple AND hamartoma AND syndromes 154 
#11 cerebellum AND dysplastic AND gangliocytom* 128 
#12 ruvalcaba AND myhre AND smith AND syndrome 24 
#13 macrocephaly AND pseudopapilledema AND multiple AND hemangiomas 0 
#14 dysplastic AND gangliocytoma AND of AND cerebellum 124 
#15 cerebellum AND dysplastic AND gangliocytoma 124 
#16 lhermitte AND duclos AND disease 387 
#17 dysplastic AND gangliocytoma AND of AND the AND cerebellum 119 
#18 riley AND smith AND syndrome 53 
#19 'myhre riley smith' AND syndrome 0 
#20 'myhre riley smith' 0 
#21 pten AND hamartoma AND tumor 299 
#22 bannayan AND zonana AND syndrome 67 
#23 hamartoma AND syndromes AND multiple 154 
#24 hamartoma AND syndromes 376 
#25 multiple AND hamartoma AND syndrome 809 
#26 bannayan AND riley AND ruvalcaba AND syndrome 202 
#27 'bannayan riley ruvalcaba' AND syndrome 186 
#28 'ruvalcaba myhre' AND syndrome 32 
#29 'bannayan zonana' AND syndrome 66 
#30 macrocephaly AND multiple AND lipomas AND hemangiomata 1 
#31 macrocephaly AND pseudopapilledema AND multiple AND hemangiomata 0 
#32 'lhermitte duclos' AND disease 385 
#33 'ruvalcaba myhre smith' AND syndrome 18 
#34 'riley smith' AND syndrome 9 
#35 #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR 
#15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR 
#26 OR #27 OR #28 OR #29 OR #30 OR #31 OR #32 OR #33 OR #34 
2,543 
#36 'meta-analysis'/exp OR 'meta-analysis' OR 'systematic review'/exp OR 'systematic review' 163,032 
#37 #35 AND #36 18 
Note    
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Appendix 2.3.4. Cochrane Database of Systematic Reviews 
Date 2014-03-17 
Database  Cochrane 
Search Strategy 
(attention, for PubMed, 
check « Details ») 
# Query Results 
#1 cowden's syndrome  0 
#2 cowden:ti  1 
#3 MeSH descriptor: [Hamartoma Syndrome, Multiple] explode all trees 1 
#4 bannayan-ruvalcaba-riley:ti,ab,kw  0 
#5 "cowden's disease":ti,ab,kw  0 
#6 "myhre riley smith syndrome":ti,ab,kw  0 
#7 "multiple hamartoma syndromes":ti,ab,kw  0 
#8 "cerebellum dysplastic gangliocytoma":ti,ab,kw  0 
#9 "cerebellum dysplastic gangliocytomas":ti,ab,kw  0 
#10 "ruvalcaba myhre smith syndrome":ti,ab,kw  0 
#11 "macrocephaly pseudopapilledema and multiple hemangiomas":ti,ab,kw  0 
#12 "dysplastic gangliocytoma of cerebellum":ti,ab,kw  0 
#13 "cerebellum dysplastic gangliocytoma":ti,ab,kw  0 
#14 "lhermitte duclos disease":ti,ab,kw  0 
#15 "cowden syndrome":ti,ab,kw  1 
#16 "hamartoma syndrome multiple":ti,ab,kw  1 
#17 "dysplastic gangliocytoma of the cerebellum":ti,ab,kw  0 
#18 "riley smith syndrome":ti,ab,kw  0 
#19 "cowdens disease":ti,ab,kw  0 
#20 "myhre-riley-smith syndrome":ti,ab,kw  0 
#21 "myhre-riley-smith":ti,ab,kw  0 
#22 "pten hamartoma tumor":ti,ab,kw  1 
#23 "bannayan zonana syndrome":ti,ab,kw  0 
#24 "hamartoma syndromes multiple":ti,ab,kw  0 
#25 "hamartoma syndromes":ti,ab,kw  0 
#26 "multiple hamartoma syndrome":ti,ab,kw  0 
#27 "bannayan riley ruvalcaba syndrome":ti,ab,kw  0 
#28 "bannayan-riley-ruvalcaba syndrome":ti,ab,kw  0 
#29 "cowden disease":ti,ab,kw  0 
#30 "ruvalcaba-myhre syndrome":ti,ab,kw  0 
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#31 "bannayan-zonana syndrome":ti,ab,kw  0 
#32 "macrocephaly multiple lipomas and hemangiomata":ti,ab,kw  0 
#33 "macrocephaly pseudopapilledema and multiple hemangiomata":ti,ab,kw  0 
#34 "lhermitte-duclos disease":ti,ab,kw  0 
#35 "ruvalcaba-myhre-smith syndrome":ti,ab,kw  0 
#36 "riley-smith syndrome":ti,ab,kw  0 
#37 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 
or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28 
or #29 or #30 or #31 or #32 or #33 or #34 or #35 or #36  
2 
#38 (pten near/3 hamartoma):ti,ab,kw  1 
#39 cowden:ti,ab,kw  1 
#40 (germline near/5 hamartom*):ti,ab,kw  0 
#41 (hamartom* near/3 (syndrom* or pten or multiple)):ti,ab  1 
#42 #38 or #39 or #40 or #41  2 
#43 #37 or #42  2 
Note  2 results: 1 Trial and 1 HTA  
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APPENDIX 3. EVIDENCE TABLES 
Appendix 3.1. NICE recommendations for genetic testing and follow-up of familial breast cancer. 
Reference CPG Search date Recommendations/conclusions Evidence 
base 
Level of 
evidence 
NICE 2013 2013  At least the following female breast cancers only in the family: 
o two first-degree or second-degree relatives diagnosed with breast cancer at 
younger than an average age of 50 years (at least one must be a first-degree 
relative) [2004] or 
o three first-degree or second-degree relatives diagnosed with breast cancer at 
younger than an average age of 60 years (at least one must be a first-degree 
relative) [2004] or 
o four relatives diagnosed with breast cancer at any age (at least one must be 
a first-degree relative). [2004] or 
 Families containing one relative with ovarian cancer at any age and, on the same 
side of the family: 
o one first-degree relative (including the relative with ovarian cancer) or second-
degree relative diagnosed with breast cancer at younger than age 50 years 
[2004] or 
o two first-degree or second-degree relatives diagnosed with breast cancer at 
younger than an average age of 60 years [2004] or 
o another ovarian cancer at any age. [2004] or 
 Families affected by bilateral cancer (each breast cancer has the same count 
value as one relative): 
o one first-degree relative with cancer diagnosed in both breasts at younger 
than an average age 50 years [2004] or 
o one first-degree or second-degree relative diagnosed with bilateral cancer 
and one first or second degree relative diagnosed with breast cancer at 
younger than an average age of 60 years. [2004] or 
 Families containing male breast cancer at any age and, on the same side of the 
family, at least: 
Observational 
studies 
Low 
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Reference CPG Search date Recommendations/conclusions Evidence 
base 
Level of 
evidence 
o one first-degree or second-degree relative diagnosed with breast cancer at 
younger than age 50 years [2004] or 
o two first-degree or second-degree relatives diagnosed with breast cancer at 
younger than an average age of 60 years. [2004] or 
 A formal risk assessment has given risk estimates of: 
o a 10% or greater chance of a gene mutation being harboured in the family 
[new 2013] or  
o a greater than 8% risk of developing breast cancer in the next 10 years [2004] 
or 
o a 30% or greater lifetime risk of developing breast cancer. [2004] 
1.4.5 Clinicians should seek further advice from a specialist genetics service for 
families containing any of the following, in addition to breast cancers: 
 triple negative breast cancer under the age of 40 years [new 2013] 
 Jewish ancestry [2004] 
 sarcoma in a relative younger than age 45 years [2004] 
 glioma or childhood adrenal cortical carcinomas [2004] 
 complicated patterns of multiple cancers at a young age [2004] 
 very strong paternal history (four relatives diagnosed at younger than 60 years of 
age on the father's side of the family). [2004] 
1.4.6 The management of high-risk people may take place in secondary care if they 
do not want genetic testing or risk-reducing surgery and do not wish to be referred to 
a specialist genetics service. [2004] 
1.4.7 Following initial consultation in secondary care, written information should be 
provided to reflect the outcomes of the consultation. [2004] 
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Reference CPG Search date Recommendations/conclusions Evidence 
base 
Level of 
evidence 
  1.6.4 Offer mammographic surveillance as part of the population screening program 
to women:  
 aged 50 years and over who have not had genetic testing but have a greater than 
30% probability of being a TP53 carrier 
 aged 60 years and over at high risk of breast cancer but with a 30% or lower 
probability of being a BRCA or TP53 carrier 
 aged 60 years and over at moderate risk of breast cancer 
 aged 60 years and over who have not had genetic testing but have a greater than 
30% probability of being a BRCA carrier 
 aged 70 years and over with a known BRCA1 or BRCA2 mutation. [new 2013] 
1.6.5 Consider annual mammographic surveillance for women: 
 aged 30–39 years at high risk of breast cancer but with a 30% or lower probability 
of being a BRCA or TP53 carrier 
 aged 30–39 years who have not had genetic testing but have a greater than 30% 
probability of being a BRCA carrier 
 aged 30–39 years with a known BRCA1 or BRCA2 mutation 
 aged 50–59 years at moderate risk of breast cancer. [new 2013] 
1.6.6 Do not offer mammographic surveillance to women: aged 29 years and under  
 aged 30–39 years at moderate risk of breast cancer 
 aged 30–49 years who have not had genetic testing but have a greater than 30% 
probability of being a TP53 carrier 
 of any age with a known TP53 mutation. [new 2013] 
MRI surveillance 
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Reference CPG Search date Recommendations/conclusions Evidence 
base 
Level of 
evidence 
1.6.7 Offer annual MRI surveillance to women: 
 aged 30–49 years who have not had genetic testing but have a greater than 30% 
probability of being a BRCA carrier 
 aged 30–49 years with a known BRCA1 or BRCA2 mutation 
 aged 20–49 years who have not had genetic testing but have a greater than 30% 
probability of being a TP53 carrier 
 aged 20–49 years with a known TP53 mutation. [new 2013] 
1.6.8 Consider annual MRI surveillance for women aged 50–69 years with a known 
TP53 mutation. [new 2013] 
1.6.9 Do not offer MRI to women: 
 of any age at moderate risk of breast cancer 
 of any age at high risk of breast cancer but with a 30% or lower probability of being 
a BRCA or TP53 carrier 
 aged 20–29 years who have not had genetic testing but have a greater than 30% 
probability of being a BRCA carrier 
 aged 20–29 years with a known BRCA1 or BRCA2 mutation 
 aged 50–69 years who have not had genetic testing but have a greater than 30% 
probability of being a BRCA or a TP53 carrier, unless mammography has shown 
a dense breast pattern 
 aged 50–69 years with a known BRCA1 or BRCA2 mutation, unless 
mammography has shown a dense breast pattern. [new 2013] 
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Appendix 3.2. Genetic variants with a significant association with breast-cancer risk in meta-analysis12 
 
Gene Variant Comparison* Frequency 
(%)
Ethnicity Numb
er 
assesse
Breast‐cancer risk Heterog
eneity
Venice criteria 
grade‡
Studies Cases Controls OR (95% CI) p value
ATM Glu1978X Carriers vs  non-carriers 0∙05 Caucasian 4 6593 3793 4∙56 (1∙35–15∙42) 0∙015 1∙000 × A A
ATM rs1800057 (Pro1054Arg) (CG+GG) vs  CC 5∙06 All ancestries 9 4998 6122 1∙20 (1∙01–1∙44) 0∙038 0∙466 B A A
CASP8 rs1045485 (Asp302His) C vs  G 13∙29 Caucasian 17 18382 19?419 0∙89 (0∙85–0∙93) 4∙65×10?8 0∙992 A A A
CASP8 rs6435074 (A34767C) A vs  C 25∙72 Caucasian 3 2677 3093 1∙12 (1∙03–1∙22) 0∙010 0∙865 A A C
CASP8 rs6723097 (A35438C) A vs  C 36∙33 Caucasian 3 2610 3040 1∙16 (1∙07–1∙25) 1∙91×10?4 0∙997 A A A
CHEK2 IVS2+1G> A Carriers vs  non-carriers 0∙39 Caucasian 5 9970 7?526 3∙07 (2∙03–4∙63) 9∙82×10?8 0∙707 × A A
CHEK2 rs17879961 (Ile157Thr) Carriers vs  non-carriers 4∙19 Caucasian 8 13311 10?817 1∙52 (1∙31–1∙77) 4∙76×10?8 0∙324 A A A
CHEK2 Deletion Carriers vs  non-carriers 0∙30 Caucasian 5 10543 8447 2∙53 (1∙61–3∙97) 6∙33×10?5 0∙419 × A A
CHEK2 1100delC Carriers vs  non-carriers 0∙49 All ancestries 47 41791 50?910 3∙10 (2∙59–3∙71) <10?20 0∙315 × A A
CTLA4 rs231775 (Thr17Ala) A vs  G 38∙54 Asian 3 2214 2288 1∙25 (1∙14–1∙37) 1∙59×10?6 0∙676 A A A
CYP19A1 (TTTA)10 R10 vs  R7 1∙76 All ancestries 13 7979 8564 1∙53 (1∙05–2∙22) 0∙027 0∙044 B B A
ERCC2 rs13181 (Lys751Gln) C vs  A 34∙62 All ancestries 33 15843 16?827 1∙13 (1∙05–1∙22) 0∙002 0∙000 A C C
ESR1 rs3020314 (C5029T) C vs  T 31∙73 Caucasian 3 5189 5614 1∙12 (1∙06–1∙18) 1∙09×10?4 0∙535 A A C
ESR1 rs1801132 (Pro325Pro) G vs  C 23∙83 All ancestries 14 10836 14?685 0∙95 (0∙90–1∙00) 0∙038 0∙297 A A C
GSTM1 Deletion Null vs  present 48∙64 All ancestries 61 21289 24?850 1∙11 (1∙06–1∙18) 8∙86×10?5 0∙003 A B C
GSTT1 Deletion Null vs  present 23∙37 All ancestries 43 16518 19?423 1∙11 (1∙03–1∙20) 0∙006 0∙005 A B C
HSD17B1 rs676387 (C‐150A) A vs  C 27∙13 Caucasian 3 11794 14?205 1∙05 (1∙00–1∙09) 0∙050 0∙278 A A C
IFNG rs2430561 (T874A) A vs  T 43∙32 All ancestries 3 324 397 1∙25 (1∙01–1∙54) 0∙039 0∙691 B A C
IGF1 rs6220 (C84864T) T vs  C 29∙50 All ancestries 3 6213 7192 1∙06 (1∙00–1∙11) 0∙048 0∙656 A A C
LRTOMT rs673478 (G‐239A) C vs  T 4∙51 Caucasian 3 607 587 1∙53 (1∙07–2∙18) 0∙020 0∙683 B A C
MTHFR rs1801133 (Ala222Val) T vs  C 32∙24 All ancestries 46 21696 27?229 1∙04 (1∙00–1∙07) 0∙041 0∙115 A A C
NBN 657del5 Carriers vs  non-carriers 0∙36 Caucasian 7 7082 9504 2∙42 (1∙54–3∙80) 1∙18×10?4 0∙736 × A A
NUMA1 rs3018301 (G‐510A) A vs  G 5∙17 Caucasian 3 606 590 1∙45 (1∙03–2∙03) 0∙033 0∙911 B A C
TP53 rs12947788 (T72C) T vs  C 8∙61 Caucasian 3 4357 5224 1∙11 (1∙01–1∙23) 0∙033 0∙568 A A C
TP53 rs12951053 (T92G) G vs  T 8∙67 Caucasian 3 4349 5247 1∙12 (1∙01–1∙23) 0∙027 0∙618 A A C
TP53 rs17878362 (16 bp Del/Ins) Insertion vs  deletion 15∙40 All ancestries 12 2961 3496 1∙15 (1∙04–1∙26) 0∙007 0∙520 A A A
TYMS 28 bp tandem repeat 2R vs  3R 33∙56 All ancestries 6 2709 3400 1∙08 (1∙00–1∙17) 0∙044 0∙734 A A C
VDR rs731236 (Ile352Met) C vs  T 35∙85 All ancestries 14 6829 8461 1∙06 (1∙00–1∙12) 0∙034 0∙357 A A C
WRN rs1346044 (Cys1367Arg) C vs  T 14∙16 All ancestries 3 2747 3555 1∙14 (1∙02–1∙27) 0∙019 0∙330 A A C
AURKA rs1047972 (Val57Ile) A vs G 16∙74 Caucasian 4 7309 10?158 0∙93 (0∙88–0∙98) 0∙011 0∙482 A A C
ESR1 rs2234693 (PvuII T397C) C vs T 39∙78 Asian 8 4563 4503 0∙94 (0∙89–1∙00) 0∙050 0∙592 A A C
GSTP1 rs1695 (Ile105Val) G vs A 19∙38 Asian 6 4634 5241 1∙07 (1∙00–1∙15) 0∙048 0∙436 A A C
MTR rs1805087 (Asp919Gly) G vs A 21∙05 Caucasian 5 5612 6671 0∙92 (0∙86–0∙99) 0∙023 0∙335 A A C
NQO1 rs1800566 (Pro187Ser) T vs C 16∙58 Caucasian 5 1488 1695 1∙27 (1∙03–1∙56) 0∙023 0∙049 A C C
TNF rs1800629 (G‐308A) A vs G 17∙01 Caucasian 9 10?664 13?048 0∙92 (0∙87–0∙96) 4∙48×10?4 0∙436 A A C
XRCC3 rs861539 (Thr241Met) T vs C 10∙98 Asian 3 1283 1120 1∙32 (1∙08–1∙60) 0∙007 0∙885 BA A 
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APPENDIX 4. LIST OF META-ANALYSES OF ASSOCIATIONS BETWEEN GENETIC 
VARIANTS AND BREAST CANCERS  
Appendix 4.1. Meta-analyses that give no or insufficient evidence for an association, or evidence of no association or protective 
effect 
Cheng, H., B. Ma, et al. (2012). "Individual and combined effects of MDM2 SNP309 and TP53 Arg72Pro on breast cancer risk: an updated meta-analysis." Mol 
Biol Rep 39(9): 9265-9274. 
Ding, D. P., X. F. He, et al. (2011). "Lack of association between XPG Asp1104His and XPF Arg415Gln polymorphism and breast cancer risk: a meta-analysis 
of case-control studies." Breast Cancer Res Treat 129(1): 203-209. 
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Gu, D., M. Wang, et al. (2010). "Lack of association between the hOGG1 Ser326Cys polymorphism and breast cancer risk: evidence from 11 case-control 
studies." Breast Cancer Res Treat 122(2): 527-531. 
He, J., T. Y. Shi, et al. (2013). "Associations of Lys939Gln and Ala499Val polymorphisms of the XPC gene with cancer susceptibility: a meta-analysis." Int J 
Cancer 133(8): 1765-1775. 
He, X. F., W. Wei, et al. (2014). "Association between the CYP1A1 T3801C polymorphism and risk of cancer: Evidence from 268 case-control studies." Gene 
534(2): 324-344. 
Henegan, C., L. Moore-Smith, et al. (2013). "Decreased TGFBR1 signaling and breast cancer." J. Clin. Oncol. 31(15). 
Hou, J., Y. Jiang, et al. (2013). "p53 codon 72 polymorphism and breast cancer risk: A meta-analysis." Exp. Ther. Med. 5(5): 1397-1402. 
Hu, J., G. W. Zhou, et al. (2010). "GPX1 Pro198Leu polymorphism and breast cancer risk: a meta-analysis." Breast Cancer Res Treat 124(2): 425-431. 
Hu, J., G. W. Zhou, et al. (2010). "MTRR A66G polymorphism and breast cancer risk: a meta-analysis." Breast Cancer Res Treat 124(3): 779-784. 
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Hu, X., Y. Fang, et al. (2013). "The association between HIF-1(alpha) polymorphism and cancer risk: a systematic review and meta-analysis." Tumor Biol.: 1-
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Hu, Z., X. Li, et al. (2010). "Three common TP53 polymorphisms in susceptibility to breast cancer, evidence from meta-analysis." Breast Cancer Res Treat 
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Huang, J., J. Huang, et al. (2013). "The Cdx-2 polymorphism in the VDR gene is associated with increased risk of cancer: a meta-analysis." Mol Biol Rep 40(7): 
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Lin, W. Y., I. W. Brock, et al. (2013). "Associations of ATR and CHEK1 Single Nucleotide Polymorphisms with Breast Cancer." PLoS ONE 8(7). 
Liu, C. and L. Liu (2011). "Polymorphisms in three obesity-related genes (LEP, LEPR, and PON1) and breast cancer risk: a meta-analysis." Tumour Biol 32(6): 
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Lu, M., F. Wang, et al. (2010). "Methionine synthase A2756G polymorphism and breast cancer risk: a meta-analysis involving 18,953 subjects." Breast Cancer 
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and 11,041 controls." Breast Cancer Res Treat 122(2): 509-514. 
Mao, C., V. C. Chung, et al. (2012). "Association between ATM 5557G>A polymorphism and breast cancer risk: a meta-analysis." Mol Biol Rep 39(2): 1113-
1118. 
Mao, C., X. W. Wang, et al. (2010). "Lack of association between CYP17 MspA1 polymorphism and breast cancer risk: a meta-analysis of 22,090 cases and 
28,498 controls." Breast Cancer Res Treat 122(1): 259-265. 
Mao, Q., L. Gao, et al. (2013). "The A10389G polymorphism of ND3 gene and breast cancer: A meta-analysis." Biomed. Rep. 1(2): 259-264. 
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APPENDIX 5. GUIDELINES FOR HEREDITARY BREAST AND/OR OVARIAN CANCER 
SYNDROME DIAGNOSTIC TESTING CRITERIA  
Woman with breast cancer + one or more of the following : 
 diagnosed ≤ 35 yrs,  
 diagnosed ≤ 50 yrs and one relative with bilateral, or ovarian, or breast < 50, or male breast cancer 
 bilateral breast cancer and both diagnosed < 50 yrs 
 ovarian cancer, any age 
 triple negative breast cancer  
 three individuals with breast cancer, one is a first degree relative (FDR) of the other two (excluding male transmitters) and one diagnosed ≤ 50 years 
 individual of ethnicity associated with higher frequency of specific mutations (eg, Ashkenazi Jewish): eligible for founder mutation testing  
 other family situations (eg multiple pancreatic cancer) with a priori chance of mutation >10% according to BRCAPRO or Evans criteria or Manchester score 
 test more than one affected relative if criteria remain positive after excluding the negative case as a phenocopy 
Woman with epithelial ovarian cancer   
 diagnosed  <70 yrs 
Male with breast cancer  
Individual with pancreatic cancer at any age with ≥ 2 FDR excluding male transmitters with breast where one diagnosed <50 or bilateral, or ovarian, or 2 more 
pancreatic cancer at any age  
Family history  
 First degree unaffected relative of any of the above on a case by case basis 
 Testing of unaffected family members should only be considered when no affected family member is available and then the unaffected family member with 
the highest probability of mutation should be tested 
The above mentioned guidelines were prepared by Karin Dahan and reviewed and approved by Y. Sznajer, K. Devriendt, V. Bours, M. Abramowicz, Ch. Verellen 
– Dumoulin, K. Keymolen, E. De Baere, G. Mortier  for the High Council for Antropogenetics at the meeting of 29/03/13. 
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APPENDIX 6. DIFFERENT CRITERIA PUT FORWARD FOR LI-FRAUMENI SYNDROME 
Classic Li-Fraumeni Syndrome 
 A proband with a sarcoma diagnosed before age 45 years, AND 
 A first-degree relative with any cancer before age 45 years, AND 
 A first- or second-degree relative with any cancer before age 45 years or a sarcoma at any age 
Li-Fraumeni Like Syndrome 
Birch definition: 
 A proband with any childhood cancer or sarcoma, brain tumor, or adrenocortical carcinoma diagnosed before age 45 years, AND 
 A first- or second-degree relative with a typical LFS cancer (sarcoma, breast cancer, brain tumor, adrenocortical carcinoma, or leukemia) at any age, AND 
 A first- or second-degree relative with any cancer before age 60 years 
Eeles definition: 
 Two first- or second-degree relatives with LFS-related malignancies at any age 
Chompret criteria  
 A proband with: a tumor belonging to the LFS tumor spectrum (soft tissue sarcoma, osteosarcoma, brain tumor, pre-menopausal breast cancer, 
adrenocortical carcinoma, leukemia, or bronchoalveolar lung cancer) before age 46 years, AND At least one first- or second-degree relative with an LFS 
tumor (except breast cancer if the proband has breast cancer) before age 56 years or with multiple tumors, OR 
 A proband with multiple tumors (except multiple breast tumors), two of which belong to the LFS tumor spectrum and the first of which occurred before age 
46, OR 
A proband who is diagnosed with adrenocortical carcinoma or choroid plexus tumor, irrespective of family history 
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APPENDIX 7. REVISED DIAGNOSTIC CRITERIA FOR COWDEN SYNDROME 
Revised PTEN hamartoma tumor syndrome clinical diagnostic criteria44 : 
Major criteria :  
 Breast cancer 
 Endometrial cancer (epithelial) 
 Thyroid cancer (follicular) 
 Gastrointestinal hamartomas (including ganglioneuromas, but excluding hyperplastic polyps; ≥3) 
 Lhermitte-Duclos disease (adult) 
 Macrocephaly (≥97 percentile: 58cm for females, 60cm for males) 
 Macular pigmentation of the glans penis 
 Multiple mucocutaneous lesions (any of the following): 
o Multiple trichilemmomas (≥3, at least one biopsy proven) 
o Acral keratoses (≥3 palmoplantar keratotic pits and/or acral hyperkeratotic papules) 
o Mucocutaneous neuromas (≥3) 
o Oral papillomas (particularly on tongue and gingiva), multiple (≥3) OR biopsy proven OR dermatologist diagnosed 
Minor criteria 
 Autism spectrum disorder 
 Colon cancer 
 Esophageal glycogenic acanthosis (≥3) 
 Lipomas (≥ 3) 
 Mental retardation (ie, IQ ≤ 75) 
 Renal cell carcinoma 
 Testicular lipomatosis 
 Thyroid cancer (papillary or follicular variant of papillary) 
 Thyroid structural lesions (e.g., adenoma, multinodular goiter) 
 Vascular anomalies (including multiple intracranial developmental venous anomalies) 
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Operational diagnosis in an individual (either of the following) 
1. Three or more major criteria, but one must include macrocephaly, Lhermitte-Duclos disease, or gastrointestinal hamartomas; or  
2. Two major and three minor criteria. 
Operational diagnosis in a family where one individual meets revised PTEN hamartoma tumor syndrome clinical diagnostic criteria or has a PTEN 
mutation: 
1. Any two major criteria with or without minor criteria; or 
2. One major and two minor criteria; or 
3. Three minor criteria. 
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APPENDIX 8. NCCN TESTING CRITERIA FOR COWDEN SYNDROME 
Major criteria:  
 Breast cancer 
 Endometrial cancer 
 Follicular thyroid cancer 
 Multiple gastrointestinal hamartomas or ganglioneuromas 
 Macrocephaly  
 Macular pigmentation of glans penis (a discolored area on the skin) 
 Mucocutaneous lesions  
o One biopsy proven trichilemmoma 
o Multiple palmoplantar keratosis (abnormal thickening of the hands and feet) 
o Multifocal or extensive oral mucosal papillomatosis 
o Multiple cutaneous facial papules (often verrucous) 
Minor Criteria:  
 Colon cancer 
 Esophageal glycogenic acanthosis (3) 
 Autism spectrum disorder 
 Mental retardation 
 Papillary or follicular variant of papillary thyroid cancer 
 Thyroid structural lesions (such as, adenoma, nodule(s), goiter) 
 Renal cell kidney carcinoma 
 Vascular anomalies (including multiple intracranial developmental venous anomalies) 
 Lipomas (benign soft tissue tumor) 
 Single gastrointestinal hamartoma or ganglioneuroma 
 Testicular lipomatosis 
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Cowden Syndrome PTEN Gene Testing Criteria 
 Individuals with a personal history of:  
 A family with a known PTEN gene mutation 
 Meeting clinical diagnostic criteria for CS 
 Bannayan-Riley-Ruvalcaba syndrome (BRR) 
 Adult Lhermitte-Duclos disease (cerebellar tumors) 
 Autism spectrum disorder and macrocephaly 
 Two or more biopsy-proben trichilemmomas 
 Two or more major criteria (one must be macrocephaly) 
CS is suspected if a person has either three major criteria without macrocephaly, one major and three minor criteria, four minor criteria, or a relative with a 
clinical diagnosis of CS or BRR. 
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Appendix 8.1. Evidence tables of cohort studies assessing cancer risk in Cowden syndrome 
Table 2 – Cancer and Lhermitte-Duclos disease (LDD) risk among Cowden syndrome patients 
Study ID Method Patient characteristics The  cumulative  lifetime  (age  70  years) 
risk (95% CI) 
Critical appraisal of study quality 
Riegert-
Johnson 
201043 
 Design: retrospective 
cohort study and 
compilation of case 
reports 
 Source of funding:  no 
extramural funding  
 Setting: Mayo clinic, US 
 Sample size: 211 
 Statistical analysis: 
Kaplan meyer 
extrapolated estimates 
 Eligibility criteria: Person with 
Cowden syndrome, either with PTEN 
pathogenic germline mutations  or not. 
 Patient characteristics: 
 age 44 ± 16 years, 64% female, 46% 
PTEN mutation 
 
any cancer diagnosis 80%, 
breast cancer [female] 81% (66%-90%),  
LDD 32% (19%-49%), 
thyroid cancer 21% (14%-29%), 
endometrial cancer 19% (0%-32%),  
renal cancer 15% (6%-32%),  
colorectal cancer was identified 16% (8%-
24%). 
Results critical appraisal:  
Is an extrapolation from a database 
in the Mayo clinic and case reports. 
Validity and applicability to the 
Belgian context is unknown 
 
 
Heald 
201041 
 Design: subselection of a 
prospective cohort study 
 Source of funding:  no 
extramural funding  
 Setting: Cleveland Clinic, 
US 
 Sample size: 127 
 Statistical analysis: 
age- and gender-
adjusted standardized 
incidence ratio (SIR) 
 Eligibility criteria: out of patients who 
met relaxed International Cowden 
Consortium (ICC) criteria (N=2548) or 
with ≥5 GI (any location) polyps, ≥1 of 
which was hyperplastic or 
hamartomatous (N=397) were 
prospectively recruited.  Out of these, 
patients having clear pathogenic 
PTEN mutations were included  
Colorectal cancer occurred in 7.1% of our 
entire series and 13% of eligible subjects 
who 
underwent at least one colonoscopy (age- 
and gender-adjusted SIR=224) 
Results critical appraisal:  
Subseries of a larger cohort, limited 
and unclear follow up time 
 
Nieuwen
huis 
201442  
 Design: Case series 
 Source of funding:  no 
extramural funding  
 Setting: various countries 
 Sample size: 180 
 Statistical analysis: 
Kaplan meyer 
extrapolated estimates 
 Eligibility criteria: out of patients who 
met relaxed International Cowden 
Consortium (ICC) criteria (N=2548) or 
with ≥5 GI (any location) polyps, ≥1 of 
which was hyperplastic or 
hamartomatous (N=397) were 
prospectively recruited.  Out of these, 
patients having clear pathogenic 
PTEN mutations were included  
Extrapolated cumulative risk per 
cancer (%) 
Any  
Male 55.7 
Female 86.6 
Breast  
Male – 
Extrapolated from case series, 
Validity of the estimation and 
applicability to the Belgian context 
unknown 
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Female 67.3 
Thyroid  
Male 5.7 
Female 24.9 
LDD  
Male 11 
Female 43.5 
Melanoma  
Male 2.3 
Female – 
Endometrial  
Female 20.7 
Colorectal  
Male 20 
Female 16.7 
Renal  
Male 2.3 
Female 8.5 
Lung  
Male – 
Female 12.2 
Tan 
201247 
 Design: retrospective 
cohort study or case serie 
 Source of funding:  no 
extramural funding  
 Setting: multicentre 
 Sample size: 368 
 Statistical analysis: 
Kaplan meyer 
extrapolated estimates 
and age-adjusted 
standardized incidence 
ratio (SIR) calculations 
 Eligibility criteria: 3,399 individuals 
meeting relaxed International Cowden 
Consortium 
 PHTS criteria were prospectively 
recruited; 368 individuals were found 
to have deleterious germline PTEN 
SIRs* for carcinomas of:  
breast 25.4, [95%CI 19.8–32.0]  
thyroid 51.1 , [95%CI 38.1–67.1] 
endometrium 42.9 [95%CI 28.1–62.8]  
colorectum 10.3 [95%CI 5.6–17.4] 
kidney 30.6 [95%CI 17.8–49.4] melanoma 
8.5 [95%CI 4.1–15.6] 
 
Estimated lifetime risks  
breast 85.2% [95%CI 71.4%–99.1%] 
thyroid 35.2% [95%CI 19.7%–50.7%] 
endometrium  28.2% [95%CI 17.1%–39.3%] 
Results critical appraisal:  
Is an extrapolation from a 
multicentre case series, follow up 
is not entirely clear 
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 colorectum 9.0% [95%CI 3.8%–14.1%] 
kidney 33.6% [95%CI 10.4%–56.9%] 
melanoma 6% [95%CI 1.6%-9.4%] 
Bubien 
201340, 
Riegert-
Johnson 
201043 
 Design: retrospective 
cohort study and 
compilation of case series 
 Source of funding:  no 
extramural funding  
 Setting: Institut Bergonie 
genetic laboratory 
 Sample size:154 
 Statistical analysis: 
Kaplan Meyer 
extrapolated estimates 
 Eligibility criteria: PHTS individuals 
with a deleterious germline PTEN 
mutation. 
SIRs* for 
female breast cancer [39.1, 95% CI 24.8 to 
58.6],  
thyroid cancer 
women [43.2, 95% CI 19.7 to 82.1]  men 
[199.5, 95% CI 106.39 to 342.03],  
melanoma  
women [28.3, 95% CI 7.6 to 35.4]  
men [39.4, 95% CI 10.6 to 100.9], and 
endometrial cancer [48.7, 95% CI 9.8 to 
142.3].  
Cumulative cancer risks at age 70  
any cancer 85% [95% CI 70% to 95%] 
female breast cancer 77% [95% CI 59% to 
91%] 
thyroid cancer38% [95% CI 25% to 56%] 
Results critical appraisal:  
Is an extrapolation from a case 
series, follow up is not entirely 
clear 
Note. SIR = Standardized incidence ratios  
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